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ABSTRACT 
EVALUATING THE EFFECTS OF A NURSE-LED INTERVENTION  
FOR DELIRIUM AND PAIN MANAGEMENT AMONG OLDER ADULTS IN THE 
SURGICAL INTENSIVE CARE UNIT 
Kara J. Pavone 
Peggy Compton  
Rosemary C. Polomano 
Delirium, a prevalent disorder in older adults, is an acute brain dysfunction characterized 
by disturbances in attention, awareness and cognition not explained by a pre-existing 
neurocognitive disorder. The ICU Liberation Executing the ABCDEF Bundle Daily 
(iLEAD) is a nurse-driven intervention aimed at reducing the consequences of delirium in 
the intensive care unit (ICU). It was posited that when nurses routinely assess non-
modifiable risk factors and manage modifiable risk factors for delirium, including those 
related to pain and pain management, patient outcomes will improve. This dissertation 
research: 1) systematically reviewed the use of the pharmacotherapy dexmedetomidine 
to treat or prevent delirium (Chapter 2); 2) compared patient outcomes in older adults 
with delirium in the surgical ICU (SICU) before and after implementation of the iLEAD 
intervention (Chapter 3); and 3) assessed the relationship among pain, its treatment 
with opioids, and the onset of delirium in the post-implementation cohort (Chapter 4). 
The pre- and post-iLEAD intervention cohorts consisted of 93 patients who developed 
delirium while admitted to the SICU at the Hospital of the University of Pennsylvania. 
The analysis evaluated the effects of implementing the iLEAD protocol on the number of 
days of delirium, SICU and hospital length of stay, 30-day readmission and 30-day 
mortality. In addition, this research examined the role of pain, pain management with 
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opioids, and delirium onset. Results from this study have meaningfully contributed to 
better informed care of older adult patients with delirium in critical care environments. 
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Chapter 1  
Introduction 
Delirium is the most common complication affecting hospitalized older adults (age  65 
years) admitted to the intensive care unit (ICU),1 totaling more than 2.6 million older 
adults in the United States (U.S.) each year.2 Delirium is defined as an acute change in 
cognition and attention not explained by a pre-existing condition or established or 
evolving dementia.3 Spending the majority of their time at the bedside, nurses are at the 
forefront of delivering care in the ICU. As the U.S. population continues to age, nurses 
will be continually challenged with identifying, managing and treating delirium. Not 
surprisingly, the economic burden of delirium is significant with total costs attributable to 
the condition estimated at $164 billion (2011 U.S. dollars) per year.4 Moreover, delirium 
contributes to distress in both patients and caregivers, and is associated with long-term 
cognitive deficits,5-10 a greater likelihood for needing residential care post-
hospitalization,5-10 and increased mortality.11-13 Delirium can be a life-threatening 
condition, yet with early identification and management it may be preventable.1 
Nurses are uniquely prepared to drive solutions to address this clinically significant 
problem by recognizing risk factors and initiating evidence-based nursing interventions. 
 To date, no single cause or mechanism for delirium has been identified. Postulated 
mechanisms contributing to delirium include; inflammation, neurotransmitter disruptions, 
physiological stressors, metabolic derangements and genetic factors.2 Commonly 
recognized risk factors for delirium in surgical intensive care unit (SICU) patients are 
pain, and its treatment with opioids.2,14,15 Pain is defined as an unpleasant physical 
and/or emotional experience related to potential or actual tissue damage,16 and the 
physiological stress associated with unrelieved pain is believed to contribute to 
delirium.15,17 The cognitive effects of the primary class of medications used to manage 
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acute pain, opioids, have also been implicated in the development of delirium.14,15,17 A 
systematic review of 14 studies found that that risk of developing delirium was 2.5 times 
greater in patients receiving opioids.18 Studying the relative roles of pain and pain 
management on the onset of delirium is vital to improve patient outcomes. 
 The 2013 Society for Critical Care Medicine Clinical Practice Guidelines for 
Management of Pain, Agitation, and Delirium (PAD)19 recommends routine monitoring of 
pain, sedation and delirium for all patients in the ICU. To encourage dissemination of 
these guidelines, the Society for Critical Care Medicine created ICU Liberation which 
utilizes the so-called “ABCDEF bundle” to help guide care (Figure 1.1). The individual 
and collective elements of the ABCDEF bundle aim to ameliorate delirium, improve pain 
management, and reduce levels of deep sedation, leading to improved outcomes for 
adult patients in the ICU. Utilizing the principles of health systems science, which 
encompass improving quality, outcomes, and costs of health care delivery for patients 
and populations within systems of medical care,20 in 2018 the Hospital of the University 
of Pennsylvania (HUP) implemented the ICU Liberation Executing the ABCDEF Bundle 
Daily (iLEAD) protocol (see APPENDIX A). The goal of iLEAD is to empower nurses to 
improve delirium-related outcomes by employing evidence-based nursing interventions.  
The overall objectives of this research were to: 1) determine if implementation of 
the iLEAD intervention resulted in fewer days of delirium, decreased length of stay in the 
SICU and hospital, and improved 30-day patient outcomes among patients in the SICU; 
and 2) evaluate the relationships among pain severity, opioid analgesic administration 
and the onset of delirium. The central hypothesis of this dissertation research is that 
implementation of the nurse-led iLEAD intervention will reduce the consequences of 
delirium in hospitalized older adults. 
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 Specifically, a retrospective pre- and post-implementation cohort study was 
performed to assess the impact of the iLEAD intervention on delirium and patient 
outcomes in critically ill patients in the SICU aged 65 years and older. A convenience 
sample of patients were examined from March to August 2017 for the pre-
implementation cohort and from March to August 2018 for the post-implementation 
cohort; the intervention was implemented in January 2018. Primary outcome measures 
were days of delirium, SICU length of stay, hospital length of stay, 30-day readmission 
rates and 30-day mortality. Secondly, in the post-implementation cohort, a cross-
sectional study examined the relationships among pain severity, pain management with 
opioids, and the onset of delirium. The specific aims were to:  
Specific Aim 1: Complete an integrative review of publications in peer-reviewed 
journals evaluating the use of a novel pharmacotherapy, dexmedetomidine, for the 
prevention and/or treatment of delirium. This review served as the foundation for the 
dissertation research aims and hypotheses by providing an increased understanding of 
the most current treatment strategies, delirium research methods, and the issues 
associated with identifying and managing delirium (Chapter 2). 
Specific Aim 2: Compare outcomes (days of delirium, SICU length of stay, hospital 
length of stay, 30-day readmission and 30-day mortality rates) between older adults in 
the pre- and post-iLEAD intervention cohorts (Chapter 3). 
Hypothesis 1: Patients’ delirium, pain  and healthcare utilization outcomes (SICU 
length of stay, hospital length of stay, 30-day readmission and 30-day mortality rates) 
will improve when nurses routinely assess and manage modifiable risk factors for 
delirium (i.e., implementing the iLEAD intervention).  
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Specific Aim 3: Evaluate the relationships among pain severity, opioid analgesic 
administration, and the onset of delirium in older adults in the SICU in the post-
intervention cohort (Chapter 4). 
Hypothesis 1: Pain severity scores will be positively correlated with the onset of 
delirium.  
 Hypothesis 2: Exposure to opioid analgesics will be positively correlated with the 
onset of delirium. 
With respect to outcomes, this work provides findings to 1) determine if early 
identification and prevention strategies associated with the iLEAD intervention result in 
fewer days of delirium and better delirium-related clinical outcomes; and 2) examine the 
relative roles of pain and opioid pain management on the onset of delirium. 
Background 
Delirium is an acute change in awareness and attention developed over a short course, 
with likely disruption to cognitive processing, that is not better described by a pre-
existing, established or evolving condition.3 Patients with delirium can experience altered 
perceptions of reality that are intense, and induce feelings of panic, uncertainty or 
distress.21 They may have trouble communicating their distress and feel misunderstood 
by family members and health care providers.  
The clinical presentation of delirium is classified into three subtypes; hyperactive, 
hypoactive, or mixed.10 With hyperactive delirium, patients may by hyperalert and exhibit 
restlessness and agitation. In contrast, those with hypoactive delirium generally present 
as lethargic or sedated and respond slowly to questions or show little purposeful 
movement. Patients with mixed delirium demonstrate the features of both hyper- and 
hypoactive delirium. Notably, older adults are more likely to express hypoactive delirium, 
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and too often, these patients go unnoticed or are mistakenly identified as having 
dementia or depression.1 
 A 2003 study by Poole and Mott reported that when caring for patients with 
hyperactive delirium, nurses’ often felt frustrated and irritated, admitting that these 
patients were difficult to work with and took up too much of their time, citing ‘‘nothing 
else gets done’’ (p. 309).22 With respect to hypoactive delirium, recent literature found 
that nurses failed to detect delirium in up to three out of four cases.23,24 Further, even 
when identified, interventions aimed at its management were not consistently 
implemented. Investigators showed that some clinicians view delirium as an inevitable 
part of a hospital stay for older adult patients, while others see it as a transient condition 
from which patients can recover without long-term consequences and clinical 
implications.4 Failure to recognize and manage delirium, stemming from its lack of 
pathognomonic features, can be a life-threatening issue for older adult patients with 
delirium.25 Taken together, these concerns represent a critical gap in clinical 
practice that results in nurses and other healthcare professionals poorly 
identifying patients with delirium and initiating new approaches to minimize its 
consequences.  
Delirium in Older Adults in the Intensive Care Unit  
Delirium is believed to occur in approximately 50% of all older hospitalized adults1 and 
70-87% of older adults admitted to the ICU following surgery.10 Following a systemic 
challenge, such as surgery, older adults are increasingly vulnerable to developing 
delirium secondary to hypothesized inflammatory processes, neurotransmitter 
disruptions, physiological stressors, and metabolic derangements.2,5,26-28 In addition, 
aging itself has been described as a risk factor for developing delirium.5,26-28 A 
substantial proportion of patients who survive delirium are likely to experience long-term 
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cognitive impairment similar to mild Alzheimer’s disease5-10,29 for up to one year post-
discharge.19 A recent study placed the odds of requiring of institutional care following 
hospitalization at rates 2.4 times higher in patients who suffer from delirium than those 
who did not.30 
In addition to being a serious health threat, delirium is a costly condition.5,10,24,29,31 An 
investigation of one-year health care costs associated with delirium in older adult 
patients showed that patients with delirium are 2.5 times more costly than patients 
without delirium.32 Supplementary costs per hospitalization attributable to delirium range 
from $16,303 to $64,421 per patient.4 While causal relationships have not been 
established specifically in SICU patients, there is evidence linking increased length of 
stay and higher mortality rates in older adult patients with delirium in general ICU 
settings.11  
Effects of Delirium on Patient and Healthcare Outcomes 
The impact of delirium on patients and health care systems is substantial. A report by 
the American Association of Retired Persons identifies delirium as one of six leading 
causes of injuries associated with hospitalization in patients over 65 years of age.33 Key 
patient and health care outcomes associated with delirium include days of delirium, 
SICU and hospital length of stay, 30-day readmissions and 30-day mortality. 
Days of Delirium and Length of Stay. Delirium is associated with longer ICU and overall 
hospital lengths of stays.34 Of patients who develop delirium in the medical ICU, the 
typical length of stay ranges from four to five days, with an average of two to three days 
of delirium.11,34,35 Ely and colleagues showed that the number of days spent in a delirious 
state predicted length of stay.34 Among a cohort of non-ventilated critically ill patients, 
delirium was associated with a one-day longer ICU stay and a two-day longer overall 
hospital stay.36 A recent systematic review estimated that the average length of stay in 
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patients with delirium in the ICU was 1 day and 9 hours longer than patients without 
delirium.37 Compared to patients who never develop delirium, patients undergoing a 
delirious episode may spend a median of 10 days longer in the hospital. At any given 
time over the course of their hospitalization, patients with delirium had an adjusted risk of 
staying in the hospital that was two times higher than those who never developed 
delirium.11 Reducing the number of days with delirium, and ICU and hospital stays would 
lessen the health and economic burdens to patients and healthcare systems. 
30-day Readmissions. Medicare and Medicaid reimbursements are reduced to hospitals 
with excessive 30-day readmissions,38 and some of the delirium-related costs cited 
above are attributed to readmissions of patients with delirium. In addition to costs, 
hospital readmissions are associated with unfavorable patient outcomes.39 Hospitals are 
now connecting with entities across the healthcare industry to implement best practices 
in reducing readmission rates, including the prevention, early diagnosis and treatment of 
delirium.39 In a study of older adult patients undergoing cardiac surgery, of those 
readmitted within 30 days for any reason, 80% had delirium during their initial inpatient 
stay.40 However, little evidence is available describing the impact of days of delirium on 
hospital readmissions, a key driver of healthcare costs.4,32,39,40  
30-day Mortality. Delirium has also been identified as an independent marker for 
increased mortality in older medical inpatients during the 12 months following 
hospitalization.41 ICU delirium is associated with a 2- to 4-fold increased risk of overall 
mortality1 with the duration of ICU delirium linked with one-year all-cause mortality.35 
Investigators demonstrated that 50% of patients who were delirious during their ICU stay 
died within one year post-hospitalization.35 A hallmark study by Ely and colleagues 
documented that in patients receiving mechanical ventilation, ICU delirium was an 
independent predictor of mortality, such that during a six-month follow-up, 34% of the 
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patients in the delirium group died versus 15% of the patients without delirium.11 This 
corresponded with a greater than three times higher risk of dying within 6-months of 
hospital discharge.11  
Nurse-Led Interventions for Delirium  
Devising innovative strategies to assess, prevent and manage delirium is well within the 
scope of nursing practice. Nurses are at the forefront of care and many evidence-based 
delirium interventions do not require a physician’s order.42,43 Nurse-led models of care 
have been used in a variety of settings, including promoting optimal aging of older 
adults,44 managing diabetes45 and cardiovascular risk,45 improving medication 
adherence,46 expanding palliative care,47 and reducing pre-surgical anxiety.48 This study 
capitalized on the clinical acumen of nurses who routinely care for older adults in the 
SICU by expanding previous nurse-driven protocols49,50 and routine clinical assessments 
to include interventions to help prevent and/or manage delirium. 
 Current strategies aimed at reducing the severity of delirium involve the recognition 
of non-modifiable risk factors and amelioration of modifiable risk factors (Figure 1.2). 
Many of these risk factors are routinely evaluated as part of a critical care nursing 
assessment. Non-modifiable risk factors for delirium outlined in the iLEAD protocol 
include: advancing age ( 65 years); history of dementia or cognitive impairment; prior 
history of delirium, stroke, neurological disease, falls or gait disorder; visual or hearing 
impairments and two or more chronic health conditions.51 Modifiable risk factors include: 
pain; sensory impairment (hearing or vision); immobilization (catheters or restraints); 
medications that have the potential for psychoactive effects on the central nervous 
system (sedatives, hypnotics, opioids, anticholinergic drugs, corticosteroids, 
polypharmacy); surgery; environment (for example, admission to an ICU); emotional 
distress; and sustained sleep deprivation.51  
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 Reliance on nurse-led interventions is especially critical in view of the lack of 
effective pharmacologic interventions to treat delirium. To date, no single 
pharmacological intervention has been demonstrated to be effective in its treatment.5 A 
number of pharmacological strategies to both prevent and treat delirium have been, and 
continue to be actively tested, including antipsychotic medications,52 
acetylcholinesterase inhibitors,53 melatonin,54 benzodiazepines,55,56 intravenous 
acetaminophen57 and gabapentin.53 In addition, numerous studies suggest that use of 
the alpha-2 agonist, dexmedetomidine, may reduce the incidence or duration of delirium 
(Chapter 2) by addressing its underlying cause, ameliorating pain or preserving sleep 
architecture.5,26,28,51,58,59 However, thus far, no single pharmacologic strategy has 
amassed enough evidence to support its role in delirium prevention or treatment. Hence, 
it is critical that nurses have a firm understanding of the risk factors for delirium and the 
non-pharmacological interventions available to help reduce the incidence and duration of 
delirium. Understanding these risk factors and treatment strategies will aid nurses in 
providing optimal care and advocating for patients’ needs.  
 The development of the ABCDEF bundle (Awake and pain free; spontaneous 
Breathing trials: Consideration of Analgesia and Sedation; Delirium; Exercise; Family 
engagement) has been well-described in the literature and published in numerous peer-
reviewed high-impact journals.60-63 While many studies have reviewed the effectiveness 
of the individual elements of the ABCDEF bundle, few have evaluated the effect of 
implementing the bundle as a whole.64-68 In January 2019, the first large scale evaluation 
of the ABCDEF bundle was published. This multicenter, prospective cohort study led by 
the Society of Critical Care Medicine ICU Liberation Collaborative included over 15,000 
adult patients (18+ years of age) from 68 ICUs (including mixed medical/surgical, 
medical, surgical/trauma, neurological, cardiac/surgical and surgical). The primary 
 
 
10 
objective of this analysis was to evaluate the relationship between ABCDEF bundle 
performance on patient and healthcare systems outcomes.68 Complete performance of 
the ABCDEF bundle (i.e., a patient day in which every eligible element of the bundle was 
performed) was associated with a lower likelihood of next-day mechanical ventilation, 
delirium, ICU readmission and 7-day mortality. The impressive results of this large-scale 
trial show that implementation of the ABCDEF bundle can improve patient and health 
system-level outcomes.  
Similarly, the iLEAD intervention evaluated in this study is based on the 
implementation of the ABCDEF bundle, with its goal being to enable nurses to monitor 
sedation, manage pain more effectively, and ameliorate delirium utilizing independent 
nursing interventions (APPENDIX A). The iLEAD intervention includes three key 
standardized assessments; the Richmond Agitation-Sedation Scale (RASS) to measure 
level of sedation, the Confusion Assessment Method for the Intensive Care Unit (CAM-
ICU) to screen for delirium, and the numeric rating scale to measure pain severity. 
Based on their assessment findings, nurses are guided to manage delirium, analgesia 
and sedation while also utilizing the interventions of early mobility and family 
engagement interventions.  
 Specifically, upon admission to the SICU, a patient’s level of sedation was assessed 
with the RASS tool, which is the first step in completing the CAM-ICU to screen for the 
presence of delirium. RASS evaluates a patient’s level of sedation on a -5 (unarousable) 
to +4 (combative) scale, with 0 corresponding to calm and alert. Patients with a RASS of 
-4 or -5 are unable to be assess by the CAM-ICU. Patients with a positive CAM-ICU 
score are evaluated for new infections, or cardiac or neurological events that may 
explain the change in their mental status. Inpatient and home medications are also 
reviewed to evaluate high-risk medications, such as opioids and benzodiazepines. 
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Nurses are then encouraged to employ at least two independent non-pharmacological 
interventions from a menu of interventions (Table 1.1) to help manage the delirium. 
Additional collaboration with the interdisciplinary team is then required to determine the 
potential cause of delirium and appropriate treatment approaches. Delirium is continually 
reassessed using the CAM-ICU every 12 hours to monitor responses to the 
interventions.  
 A limited number of studies have examined the effectiveness of these independent 
nursing interventions, although the use of such supportive measures has nevertheless 
become standard practice on the basis on clinical experience and lack of adverse 
effects.10 A systematic review of 39 trials in non-ICU patients concluded that 
multicomponent interventions (interventions included an educational component, 
individualized care, reorientation, and early mobilization) concurrently targeting several 
risk factors are effective in prevention of delirium (reduction in incident of delirium by 
approximately one-third).69 The review cites moderately strong evidence to support the 
use of these interventions in delirium prevention, but provide less robust evidence to 
support decreasing severity or duration of delirium.69 Reducing known risk factors and 
precipitants of delirium may decrease the factors contributing to, and possibly 
prolonging, an episode of delirium.70 Ultimately, more research is needed to understand 
the benefits of individual nursing interventions on reducing the number of days of a 
delirious episode and other delirium-related patient outcomes.  
Pain  
Pain is a potent and common stressor present in approximately 80% of critically ill 
patients admitted in the SICU.71 Related to the surgical incision, and/or tissue 
manipulation and removal during surgical procedure, moderate to severe pain is present 
in up to three out of four postsurgical patients.72 In addition, the majority of patients 
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regard some degree of pain following surgery as ‘‘necessary’’ (p. 1093).72 Due to its 
subjective nature, pain can only be reported by the individual who is experiencing it.73 
Verbal rating scales, numerical rating scales and visual analogue scales provide simple, 
effective, and minimally invasive measures of pain intensity; however, many patients 
admitted to the ICU are unable to report their pain because of mechanical ventilation, 
neuromuscular blockade, or deep sedation.74 When pain is not routinely assessed and 
managed, patients may be inappropriately be given sedative medications rather than 
analgesic medications.75 Payen and colleagues76 found that when routinely assessed for 
pain, mechanically ventilated patients were more likely to receive analgesic medications 
(non-opioids or opioids) and less likely to receive sedatives (in particular, deliriogenic 
benzodiazepines) than patients who never had a pain assessment.76  
 Older adults may be stoic or reticent about reporting pain for fear of complaining.77 A 
review by Schofield estimates that 50% to 60% of patients aged over 75 years suffer 
pain or discomfort, yet are consistently less likely than younger patients to receive 
appropriate pain management.77 In addition, both the peripheral and central nociceptive 
nervous systems are affected by the aging process, including reductions in the 
concentration of serotonin receptors and GABA synthesis, which are important 
modulators of pain, resulting in slowing of endogenous inhibitory pain process and 
increased sensitivity to pain in older adults.78 Finally, older adults are more likely to have 
age-related changes in pharmacokinetics and pharmacodynamics related to analgesic 
medication administration. Taken together, these changes in pain processing, 
physiologic pain response and medication metabolism in older adults have important 
implications in the management of their pain.  
 In critical care patients, suboptimal pain management has been associated with an 
array of negative consequences, including increased cost of care, decreased quality of 
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life, prolonged opioid use during and after hospitalization, and increased morbidity.77,79-81 
Uncontrolled pain is a stressor and can have harmful effects on several different body 
systems including, cardiovascular, respiratory, musculoskeletal and, most notably, 
cognitive function.17 Furthermore, unrelieved moderate to severe pain may lead to 
persistent or chronic pain.79 The prevalence of persistent pain following major surgeries 
remains between 10% and 30%.82 More aggressive analgesic measures are needed to 
reduce the incidence and intensity of acute pain, and to prevent the evolution from acute 
to chronic pain.79 In addition to chronic post-surgical pain, the consequences of 
insufficient pain management also include sleep deprivation, fatigue, anxiety, and 
delirium.82  
Delirium and Pain  
In the literature, untreated pain is frequently identified as a precipitating factor for the 
development of delirium.19,80,81 In fact, in the iLEAD intervention, pain is identified as a 
primary modifiable risk factor for delirium. However, there is surprisingly limited evidence 
to support a causal relationship between pain and the development of delirium. Because 
the relationship between pain and delirium has not been well-elucidated, there is no 
evidence-based strategy to both pharmacologically manage pain and prevent delirium in 
critically ill patients. Few studies have examined the SICU population and how the 
presence of pain contributes to the occurrence of delirium,81 and conflicting data exist 
regarding this relationship. Vaurio and colleagues in their investigation with older adults 
scheduled for non-cardiac surgery concluded that pain was independently associated 
with the development of delirium.81 In that any patient reports of pain are typically and 
aggressively addressed with opioid administration in the inpatient setting, newer 
evidence has not sufficiently drawn definitive conclusions about the relationship of pain 
and delirium.  
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Delirium and Opioid Analgesia  
To date, pain management in the ICU has relied almost exclusively on opioid 
administration.14,15 The mu-opioid receptors are involved in the regulation of sensory and 
affective components of the pain experience. The most common opioids analgesics 
used include; morphine, oxycodone, hydromorphone, hydrocodone, and fentanyl. For 
acute pain, opioids are generally administered by intravenous and oral routes. Literature 
suggests that pain management with opioids may be a precipitating factor for the 
development of delirium.15 The method or mode of administration (oral, patient-
controlled analgesia, neuraxial, intravenous) of opioid administration appears to play a 
more important role in the development of delirium than absolute dose, likely due to 
onset of action.15 For example, the use of oral opioid analgesic as the primary means of 
pain control is less likely to induce delirium compared to intravenous patient-controlled 
analgesia.81 As previously noted, when prescribing pain management for older adults, it 
is important to consider age-related changes in pharmacokinetics and 
pharmacodynamics of opioid medications. Due to slowed drug metabolism, older adults 
are more susceptible to the central nervous system depressant effects of these 
medications. 
 Opioid use has been implicated in development of delirium in patients admitted to the 
ICU83 and across various hospital settings.18 These medications have psychoactive and 
depressant effects on cortical function, including cognitive performance, which may 
contribute to the decline in cognitive function hallmark of delirium.14,84 Opioids inhibit 
calcium channel opening by binding to regulatory G-protein-coupled mu-opioid 
receptors, and thereby block presynaptic terminal depolarization in cholinergic 
pathways.85 This deficit in cholinergic activity is thought to contribute to delirium.14 In a 
study of 216 patients in a medical/surgical ICU, 40 patients developed delirium (19%), 
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and use of opioid analgesics (morphine and epidural) was strongly correlated to the 
development of delirium.83 A systematic review of 9 studies reported opioid use in both 
medical, surgical and medical/surgical ICU settings, and concluded that opioids are a 
risk factor for the development of delirium.18 However, these studies have limited 
generalizability and were noted to be of low to moderate quality evidence.18,83 Therefore, 
the role of opioid analgesics in the development and duration of delirium requires 
additional clarification.  
Summary 
Delirium is a significant and costly problem for older adults in the ICU. It is commonly 
under-recognized and undertreated, and the consequences are not only evident in 
length of SICU and hospital stay, but in the more worrisome outcomes of 30-day 
readmissions and mortality. Empirical evidence for independent nurse-led interventions 
to mitigate the development and duration of delirium is accumulating, and this evaluation 
of the iLEAD intervention at HUP contributes to this body of knowledge. Interestingly, 
both pain and opioid administration are identified as independent risk factors for the 
development of delirium,15 suggesting that by attempting to ameliorate one risk factor 
(pain), nurses may in fact be contributing to another (delirium).  Examination of the 
relative roles of pain and opioid administration on the onset of delirium experienced by 
this population provides the foundation for evidence-based guidelines on pain 
management approaches which minimize negative outcomes related to delirium.  
Significance  
The dissertation research is significant in two principal ways. First, this work focuses on 
a uniquely nurse-led intervention. While iLEAD is described as an interdisciplinary 
intervention, nurses are the key stakeholders driving this intervention forward. Their 
clinical expertise and front-line responsibilities make nurses uniquely qualified to 
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champion this effort and facilitate the prevention and management of delirium with the 
interdisciplinary care team. Although nurse-led interventions have been demonstrated to 
improve patient outcomes in multiple health problems (diabetes,45 cardiovascular 
disease,45 medication adherence,46 palliative care,47 pre-surgical anxiety44), this is one of 
the first evaluations to determine the impact of iLEAD bundled independent nursing 
interventions to treat the significant and costly problem of ICU delirium.  
 Second, pain is commonly cited as a primary risk factor for the development of 
delirium.86 However, close examination of the literature reveals that there is little 
empirical evidence to support this oft-cited causal relationship. Further, the role of 
pain management with opioids in the development of delirium requires explication. If, in 
fact, untreated pain results in delirium, analgesia should improve delirium outcomes, 
however the depressant cognitive effects of the analgesics most commonly used to treat 
pain, opioids, may worsen delirium. This raises the question as to whether opioids 
administered to counter pain-induced delirium contribute to its development. This study 
is among the few to characterize the relative roles of pain and opioid administration on 
the onset of delirium.  
In summary, the overall contribution of this study is to describe the effectiveness of 
the nurse-led iLEAD intervention to reduce the burden of delirium and its associated 
adverse outcomes and to examine two modifiable risk factors associated with delirium 
(i.e. pain, opioid administration). The variables examined in this study are described in 
APPENDIX B. This dissertation research: 1) evaluates a nurse-led identification, 
treatment and management strategy for delirium; 2) expands knowledge of delirium-
related patient outcomes (days of delirium, length of stay, readmissions, mortality); and 
3) facilitates continued investigation into the link between pain, opioid pain management 
and the onset of delirium. Overall, this dissertation research has important implications in 
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moving forward nurse-driven approaches to the clinical care of aging adults in critical 
care environments at risk for experiencing delirium.  
Chapter Aims and Rationale 
The major goals of this dissertation research were to: 1) conduct an integrative review of 
the literature to examine the use of dexmedetomidine to prevent and/or treat delirium 
(Chapter 2); 2) determine if identification and prevention strategies associated with the 
nurse-led iLEAD intervention result in fewer days of delirium and better delirium-related 
clinical outcomes (Chapter 3); and 3) explicate the relative roles of pain and opioid pain 
management on the onset of delirium (Chapter 4). 
Chapter 2 
Aim: To date, no single pharmacological intervention has been shown to be effective in 
treating or preventing delirium. Studies suggest the novel alpha-2 agonist, 
dexmedetomidine, may reduce or prevent delirium due to its unique actions on sleep 
preservation and pain control. An integrative review of the literature to determine if use 
of dexmedetomidine was associated with a lower incidence and/or duration of delirium 
as compared to other non-dexmedetomidine pharmacologic strategies was conducted. 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines directed this integrative review. A table of evidence reviews 16 high-quality 
studies using dexmedetomidine for the prevention or treatment of delirium in three 
patient populations: mechanically ventilated, those undergoing cardiac surgery and 
those undergoing non-cardiac surgery. This work informed the aims addressed in the 
data-based papers to follow, and presented a unique integrative review evaluating the 
effects of dexmedetomidine for the prevention or treatment of delirium. This work has 
been published in Heart & Lung: The Journal of Acute and Critical Care (2018 impact 
factor 1.73). 
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 Rationale: The results of this review found that postoperative administration of 
dexmedetomidine may reduce delirium in patients, particularly following cardiac surgery. 
Further research is needed to determine the benefits of dexmedetomidine in patients on 
mechanical ventilation and optimal timing and duration of administration. The themes 
identified in this review informed the basis for this dissertation research and future lines 
of inquiry. Specifically, the limitations of pharmacotherapy in treating delirium became 
evident, and sorely missing from the studies reviewed was any discussion of the use or 
effect of nurse-led interventions on reported outcomes. Further, the suggestion that 
dexmedetomidine efficacy could be attributed to its analgesic effects, and therefore 
opioid-sparing approaches, provided the foundation for research questions about the 
relationships between pain, opioid pain management and delirium.  
Chapter 3 
Aim: Although protocolized nurse-led interventions have been evaluated for several 
health conditions or diseases, the success of these in the management of SICU delirium 
in older adult patients has not been empirically examined. Outcomes in older adult 
patients in the SICU before and after the implementation of the iLEAD intervention, a 
nurse-driven delirium assessment, treatment and management protocol, were 
compared. Chapter 3 has been formatted for possible publication in The Joint 
Commission Journal on Quality and Patient Safety (2018 acceptance rate 26.4%) 
describing delirium outcomes before and after implementation of iLEAD in the SICU at 
HUP. 
 Rationale: By 2060, it is estimated that older adults will comprise nearly 25% of the 
population. Consequently, nurses in acute care settings will be challenged to care for 
higher numbers of older adults experiencing delirium in future decades. Literature that 
specifically addresses the effectiveness of delirium management interventions for older 
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adults admitted to the SICU is limited, and primarily focuses on comparing various 
pharmacologic approaches. This data-based paper compares the number of days of 
delirium and patient-centered delirium outcomes following implementation of the nurse-
led iLEAD intervention. This paper highlights the contributions of nurses in integrating 
iLEAD into routine clinical care and explicates the impact of independent nurse-initiated 
interventions on patient outcomes. 
Chapter 4 
Aim: Literature suggests that pain and opioid administration may each independently be 
precipitating factors in the development of delirium. However, there is diverse and limited 
evidence to support these relationships, particularly among older adults in the SICU. As 
such, the relative roles of pain, opioid analgesic administration and the onset of delirium 
were examined. The findings for this cross-sectional analysis are reported in Chapter 4 
and formatted for publication in the American Journal of Critical Care (2018 impact factor 
2.055) exploring the relative roles of acute pain and opioid administration on the onset of 
delirium experienced by patients in the SICU at HUP.  
 Rationale: Limited evidence suggests that pain and use of opioids for pain 
management are precipitating factors in the development of delirium. However, empirical 
evidence to support the association between pain and delirium is sparse. In addition, 
literature that specifically addresses the effects of pain and pain management on 
delirium for older adults admitted specifically to the SICU is limited. This cross-sectional 
analysis evaluated the relationships among pain, its management with opioids, and the 
onset of delirium. This data-based paper is among the first to specifically evaluate the 
relationships among the onset of delirium, pain and pain management following 
implementation of the iLEAD intervention.  
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Figures and Tables 
 
 
Figure 1.1 ABCDEF Bundle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Conceptual Model of the iLEAD Intervention, Delirium and its 
Consequences 
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Table 1.1 Independent Non-Pharmacologic Nursing Interventions for Management 
of Delirium 
Manage pain (repositioning, massage, etc.) Provide music therapy 
Use communications tools Adjust room temperature 
Ensure adequate nutrition, assist with 
feeding 
Manage bowel and bladder 
Constantly provide reorientation Provide cognitively simulating activities 
Expose to sunlight Manage thirst sensation 
Provide physical activity Manage stimuli from tubes, lines and drains 
Encourage family engagement Avoid physical restraints 
Have eye glasses or hearing aids available 
at the bedside 
Provide sleep hygiene with 2-4-hour blocks of 
minimal interruptions and noise minimization  
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Chapter 2  
Evaluating the use of dexmedetomidine for the reduction of delirium:  
An integrative review1 
Abstract 
Delirium, an acute change in cognition and attention not secondary to a pre-existing 
condition or dementia, affects nearly 40,000 hospitalized older adults in the United 
States every day. Delirium is associated with increased healthcare costs of $16,303 to 
$64,421 per patient. To date, no single pharmacological intervention is effective in 
preventing or treating delirium in critically ill patients. Evidence suggests the alpha-2 
agonist, dexmedetomidine, may reduce or prevent delirium. An integrative review 
examined whether dexmedetomidine was associated with a lower incidence of delirium 
compared to other analgesic and sedation strategies. PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) guided this review and 16 
publications met quality criteria for inclusion. These studies support that postoperative 
administration of dexmedetomidine may reduce delirium in patients, particularly following 
cardiac surgery. Further research is needed to determine the benefits of 
dexmedetomidine in patients on mechanical ventilation and optimal timing and duration 
of administration.  
 
 
 
                                                 
 
1 This chapter is the author’s original work. A final version of this manuscript is published as Pavone, K. J., Cacchione, P. 
Z., Polomano, R. C., Winner, L. & Compton, P. Evaluating the use of dexmedetomidine for the reduction of delirium: An 
integrative review. Heart Lung 47, 591-601, doi:10.1016/j.hrtlng.2018.08.007 (2018). © 2018 Elsevier Inc. No 
modifications are permitted without the permission of the copyright holder.  
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Introduction  
Delirium, a common problem for hospitalized older adults particularly after surgery or 
with acute illness, is defined as an acute change in cognition and attention not described 
by a pre-existing condition, established or evolving dementia.1 Delirium contributes to 
distress in patients, caregivers and families, and more seriously is associated with 
increased mortality,2-4 long-term cognitive deficits, and a greater likelihood for requiring 
post-hospitalization residential care.5-10 Older adult patients (ages  65) are more 
vulnerable to developing delirium as a result of surgery and acute illness than younger 
patients, and aging itself is a risk factor for developing delirium. By 2060, it is estimated 
that the number of older adults in the United States will rise to 98.2 million, nearly 25% of 
the population. Consequently, healthcare providers in acute care settings will be 
expected to care for higher numbers of older adults with delirium in future decades.  
To date, no single pharmacological intervention has been shown to be effective in 
treating delirium.5 Multiple variables contribute to the development of delirium, including 
underlying health conditions, but the pathophysiology of delirium remains poorly 
understood. Current interventions for the prevention of delirium involve the recognition 
and amelioration of modifiable risk factors. These risk factors include pain, immobility, 
sleep disturbances, and exposure to medications that have the potential for 
psychoactive effects on the central nervous system such as opioids and 
benzodiazepines.11 A number of pharmacological strategies to both prevent and treat 
delirium have been, and continue to be, highly tested including, antipsychotic 
medications,12 acetylcholinesterase inhibitors,13 melatonin,14 benzodiazepines,15,16 
corticosteroids, statins and gabapentin.13 Thus far, no single strategy has amassed 
enough evidence to support its role in delirium prevention or treatment.  
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Studies purport that dexmedetomidine (Precedex©) may reduce or prevent delirium.5,17-
24 Dexmedetomidine, approved by the FDA in 1999 for short-term sedation (not to 
exceed 24 hours), is the most specific alpha-2 receptor agonist currently used in clinical 
care.25 Dexmedetomidine, like clonidine, exerts its anti-nociceptive effects in two ways. 
Primarily, it acts at alpha-2 receptors in the descending inhibitory nociceptive pathway in 
the spinal cord.26,27 Dexmedetomidine helps down-regulate nociceptive information 
transmission by disinhibiting inhibitory interneurons, which in turn block early nociceptive 
information transmission into the spinal cord by dorsal root ganglion neurons.26 
Dexmedetomidine also exerts a key anti-nociceptive effect by decreasing arousal.  
Traditionally, dexmedetomidine is administered as an anesthetic adjunct in non-
intubated patients prior to and/or during surgical and other procedures. Additionally, it is 
indicated for sedation of intubated and mechanically ventilated patients in critical care 
settings. Patients who are sedated with dexmedetomidine are arousable and responsive 
in a manner that is similar to that seen in people who are sleeping.28,29 The 
neurophysiological and behavioral characteristics of the sedative state induced by 
dexmedetomidine closely resemble non-rapid eye movement sleep.28,30,31 
It is hypothesized that dexmedetomidine may reduce delirium by addressing its 
underlying cause or ameliorating pain.5,17-21 Maldonado and colleagues5 attribute an 
intrinsic “delirium-saving” property of all alpha-2 adrenoceptor agonists, which typically 
have minimal effects on cognitive impairment. They postulate that dexmedetomidine 
may lessen the occurrence and severity of delirium because it decreases the need for 
gamma-Aminobutyric acid (GABA)ergic agents, benzodiazepines and opioids typically 
required for sedation and analgesia.11,32 In addition, dexmedetomidine has limited effects 
on the cholinergic system, which is involved in cognitive function and in the subsequent 
development of delirium.33 It has also been proposed that dexmedetomidine may reduce 
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delirium by ameliorating pain, an independent risk factor for the development of 
delirium.34-37 As such, an integrative review to examine whether use of dexmedetomidine 
was associated with a reduction in delirium as compared to other analgesic and sedation 
strategies was conducted.  
Methods  
Our literature search, article selection, and evaluation were guided by PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) for quality of 
reporting for systematic and meta-analyses.38 A literature search was conducted with 
National Library of Medicine Medical Subject Headings (MeSH) terms dexmedetomidine 
and delirium. The search was further refined by keywords (elderly, intensive care, critical 
care and clinical trial) entered into the electronic search. Studies published between 
1986 and 2017 were reviewed by using three electronic databases: PubMed, Scopus 
and Embase. Inclusion criteria included: 1) articles written in English; 2) search terms 
found in the title or as keywords; 3) study sample defined as adult population; and 4) 
delirium as a primary or secondary outcome. Exclusion criteria included: 1) articles 
related to the pediatric critical care setting; 2) mixed adult/pediatric studies; 3) case 
studies, commentaries, expert consensus, editorials and grey literature; and 4) chronic 
or cancer pain populations. The search strategy conducted with a health science 
librarian yielded 309 articles, 53 titles and keywords that met inclusion criteria and were 
screened for relevancy. Upon further review, 20 articles were retained and evaluated for 
scientific rigor of study design, methods and analysis. After reading the full text, four 
additional articles were excluded not meeting the inclusion and exclusion criteria, leaving 
a total of 16 articles chosen for analysis and review (Figure 2.1). Using the Johns 
Hopkins Nursing Evidence-Based Practice Research Appraisal Guidelines,39 the design 
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and quality of evidence of the articles were assigned an evidence level of I, II, III, IV or V 
and graded A (high quality) B (good quality) or C (low quality or major flaws) (Table 2.1).  
Study Characteristics 
The 16 articles selected for review included: seven randomized, double-blind, controlled 
studies; four randomized, open label, controlled studies; and five retrospective cohort 
analysis studies (Table 2.2). All articles were published in peer-reviewed journals 
between 2007 and 2017. For nine studies, delirium was the primary outcome measure. 
Delirium was a secondary outcome for seven of the studies. The primary outcome 
measurements of these studies were: 1) percentage of time within target Richmond 
Agitation-Sedation Scale (RASS) range40; 2) mortality and postoperative major adverse 
cardio-cerebral events41; 3) time to randomization and proportion of RASS assessments 
in the first 48 hours in the light to deep sedation range42; 4) time on mechanical 
ventilation43; 5) incidence of agitation in the post anesthesia care unit (PACU)44; 6) in-
hospital, operative and 1-year mortality45; and 7) mortality and ventilator free days.46 Of 
the studies reporting the mean age for the dexmedetomidine group, the sample 
population ranged from 55 to 74 years of age. 
Identification of Delirium  
The Confusion Assessment Method (CAM) and the CAM for the Intensive Care Unit 
(CAM-ICU) were most commonly used to identify delirium. These tools screen for 
delirium based on four features: 1) acute onset of mental status changes or a fluctuating 
course; 2) inattention; 3) disorganized thinking; and; 4) altered level of consciousness. 
For delirium to be present, a patient must display features 1 and 2, with either 3 or 4.47,48 
Both the CAM and CAM-ICU have been derived and validated against diagnostic criteria 
established by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V),1 the 
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“gold standard” for diagnosing delirium. The CAM and CAM-ICU are the most widely 
used tools to identify delirium.48 
Results 
Across studies, there was relative consistency in how delirium was identified. Twelve of 
the studies relied on the CAM-ICU for evaluation of delirium; one study utilized a trained 
neuropsychiatrist,19 and three studies defined the development of delirium as “the 
presence of illusions, confusion, cerebral excitement having a comparatively short 
course.”41,45,49 The studies retained for this review were delineated into three patient 
subgroups; those: 1) on mechanical ventilation; 2) having had cardiac surgery; and 3) 
having had non-cardiac surgery.  
Mechanical Ventilation  
Shehabi and colleagues (2013)42 evaluated early goal-directed sedation with 
dexmedetomidine compared to standard sedation with midazolam and/or propofol. The 
results showed dexmedetomidine resulted in an equal portion of patients who 
experienced delirium during the study period (38%; p = 0.97).42 The MENDS 
(Maximizing Efficacy of Targeted Sedation and Reducing Neurocognitive Dysfunction)15 
study compared dexmedetomidine and lorazepam. Authors concluded that patients who 
received dexmedetomidine had more days alive without delirium and coma compared to 
those who received lorazepam (median 7 verses 3 days; p = 0.01). A subgroup analysis 
of these data showed no significant difference in the development of delirium between 
septic and non-septic patients.16 Following this line of investigation, the DESIRE 
(Dexmedetomidine for Sepsis in Intensive Care Unit Randomized Evaluation) trial 
prospectively evaluated patients with and without sepsis,46 and again reported the 
incidence of delirium to be not statistically significantly different between groups.46 Riker 
and colleagues40 compared midazolam to dexmedetomidine. The prevalence of delirium 
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in patients treated with dexmedetomidine was 54.0% compared to 76.6% in patients 
treated with midazolam (22.6% difference, 95% CI: 14% to 33%; p < 0.001).  
Cardiac Surgery 
Maldonado and colleagues19 compared dexmedetomidine to propofol and midazolam. 
The incidence of delirium for the entire study population was 34%, with those receiving 
dexmedetomidine just 3%, compared to 50% for propofol, and 50% for midazolam (p < 
0.001).19 Wanat and colleagues43 also compared the use of dexmedetomidine and 
propofol, however the incidence of delirium (any vs. none) was similar (9.09% vs. 7.52%, 
p = 0.747) across both groups. Djaiani and colleagues also reported no statistically 
significant difference between patients in receiving dexmedetomidine (16 of 91, 17.5%) 
versus propofol (29 of 92, 31.5%) (Odds ratio, 0.46; 95% CI, 0.23 to 0.92; p = 0.028).50  
 Li and colleagues studied dexmedetomidine in a placebo-controlled trial, and the 
authors found no significant difference between the two groups in the incidence of 
delirium, 4.9% (7/142) in the dexmedetomidine group vs 7.7% (11/143) in the control 
group (OR; 0.62, 95% CI, 0.23-1.65; p = 0.341). Lastly, Shehabi and colleagues40 
compared dexmedetomidine to morphine-based treatment regimens in the DEXCOM 
study (DEXmedetomidine COmpared to Morphine). Of note, this is the only study 
retained in this review that evaluates dexmedetomidine against an opioid comparator. 
The overall incidence of delirium within five (5) days was 11.7% (35 out of 299 patients) 
with 8.6% occurring in the dexmedetomidine group compared to 15% in the morphine 
group (RR, 0.571, 95% CI 0.256 to 1.099, p = 0.088).40 Several retrospective studies by 
Fuhai and colleagues41,45,49 have also examined the effect of dexmedetomidine on the 
development of delirium in different groups of cardiac surgery patients. All three 
investigations found a statistically significant reduction in the incidence of delirium 
between dexmedetomidine and non-dexmedetomidine groups.  
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Non-Cardiac Surgery 
The effect of dexmedetomidine has also been assessed in studies of patients 
undergoing non-cardiac surgical procedures. These studies include heterogeneous 
surgical patient populations, and they are distinct from the mechanical ventilation 
subgroup in that they include a defined surgical period. Yang and colleagues (2015)44 
examined whether dexmedetomidine sedation could decrease agitation and delirium 
after free flap maxillofacial surgery. These authors detected that the incidence of 
delirium was similar between the dexmedetomidine (5.1%; 2 of 39 patients) and control 
(saline) groups (12.5%; 5 of 40 patients; p = 0.432).44 Next, Su and colleagues (2016)51 
investigated a prophylactic low-dose dexmedetomidine versus placebo in patients 
undergoing abdominal, thoracic, spinal and transurethral surgeries. Postoperative 
delirium was observed in just 32 (9%) patients receiving dexmedetomidine compared to 
79 (23%) patients receiving placebo (OR, 0.35, 95% CI 0.22 – 0.54; p <0.0001). Deiner 
and colleagues52 also studied dexmedetomidine versus placebo in spine, thoracic, 
orthopedic, and/or general surgery patients, however they found no statistically 
significant difference in post-operative delirium between the dexmedetomidine and 
placebo groups.  
Discussion 
Overview of findings  
Across studies, there was significant variability in the timing of administration of 
dexmedetomidine including preoperative, intraoperative and postoperative, and sample 
populations (e.g., mechanically ventilated patients not following a surgical procedure, 
cardiac surgery patients, or other surgical patients). Within the cardiac surgery sample, 
there was evidence favoring the use of dexmedetomidine to reduce the incidence of 
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delirium, while the mechanically ventilated and non-cardiac surgery samples helped 
generate hypotheses to explain the unsuccessful outcomes with administration.  
Pre-operative Administration  
Pre-operative administration of dexmedetomidine was observed in cardiac surgery 
patients as demonstrated by Li and colleagues53 and a non-cardiac surgery population 
as demonstrated by Deiner and colleagues.52 Neither instance resulted in a reduction of 
delirium following administration of dexmedetomidine. In both studies, dexmedetomidine 
was started upon entering the operating room and continued for either two hours 
postoperatively (Deiner et al; infusion rate 0.5 μg · kg-1 · h-1) or until extubation (Li et al; 
infusion rate 0.1 μg · kg-1 · h-1). Both studies specifically targeted older adult patients 
(aged greater than 68 and 60 years respectively) and were placebo controlled (normal 
saline). As such, propofol and or midazolam were allowed for sedation in the treatment 
(dexmedetomidine) group. This older adult population presented with additional 
vulnerability to the development of delirium associated with the aging process. The 
presence of intraoperative general anesthetics, in combination with postoperative 
sedation with propofol and or midazolam, may result in blocking the intrinsic properties 
of dexmedetomidine thought to prevent delirium. A second consideration for the lack of 
efficacy may be due to the short time course of drug administration in the study by 
Deiner and colleagues (only two hours postoperatively), and the low infusion rate (0.1 μg 
· kg-1 · h-1) in the study by Li and colleagues. Preoperative administration with 
concomitant propofol or midazolam appears to reduce the efficacy of dexmedetomidine 
in the reduction of postoperative delirium. Large scale clinical trials should be conducted 
with higher infusion rates and longer durations of drug administration to see if 
preoperative use of dexmedetomidine may be effective in prevention of postoperative 
delirium.  
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Intraoperative Administration 
Intra-operative administration of dexmedetomidine was observed in three cardiac 
surgery studies (Maldonado et al.19; Fuhai et al. 201341; and Fuhai et al. 201449); and 
one non-cardiac surgery study (Yang et al.44). All three of the cardiac surgery studies in 
this group report a decrease in the incidence of delirium (Maldonado et al.19 Fuhai et al. 
201341 and Fuhai et al. 201449), while the one non-cardiac study reported no statistically 
significant reduction of delirium (Yang et al.44) after use of dexmedetomidine in the intra-
operative period. Dosing across all four studies was similar (0.2 – 0.7 μg · kg-1 · h-1) and 
drug administration occurred in all instances 60 minutes prior to the end of surgery and 
continued for no more than 24 hours. The total length of surgical time reported by Yang 
and colleagues was 399.1  94.6 minutes in the dexmedetomidine group and 402.7  
92.6 minutes in the control group. This total surgical time is significantly longer than 
reported in the cardiac surgery study by Maldonado and colleagues (dexmedetomidine 
group: 302  106 minutes; control group 306  97 minutes). As in the preoperative 
studies, the extended length of time under general anesthesia may have influenced the 
efficacy of intraoperative dexmedetomidine in the study by Yang and colleagues. To test 
this hypothesis, additional studies would need to evaluate the duration of surgical time in 
relation to dexmedetomidine dosing. However, these results do show promise that 
dexmedetomidine is effective in reducing the incidence of postoperative delirium in 
cardiac surgery patients. An important limitation of this group however, is two of the 
cardiac surgery studies are retrospective analyses. Therefore, prospective studies are 
still needed to validate this mechanism.  
Postoperative Administration  
Postoperative administration of dexmedetomidine was observed in four cardiac surgery 
studies (Shehabi et al.40; Wanat at al.43; Cheng et al.45 and Djaiani et al.50) and one non-
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cardiac surgery study (Su et al.51). The incidence of delirium was reduced in four out of 
five studies (three cardiac surgery and one non-cardiac surgery). Patients undergoing 
cardiac surgery are at an increased risk of developing delirium due of the complexity of 
the surgical procedure and the high risk of postoperative complications.19,41,45,53 First line 
therapy for sedation in patients admitted to the cardiac ICU is typically propofol and/or 
midazolam. This result is highly suggestive that dexmedetomidine given postoperatively 
may be able to overcome the neurochemical milieu of general anesthesia. All studies in 
this group used active comparators (morphine, propofol and/or midazolam) which 
reduced the administration of these agents in the dexmedetomidine group possibly 
contributing to the efficacy of treatment with dexmedetomidine. Sedation in patients 
admitted to the cardiac ICU is typically managed with propofol and/or midazolam which 
have both been shown to increase rates of delirium. The reduction of these agents may 
explain the increased efficacy of dexmedetomidine as the sole sedative agent. Study 
drug dosing across studies was similar ranging from 0.1 – 0.7 μg · kg-1 · h-1, titrated to 
the desired clinical effect. In the four studies which showed effectiveness of 
dexmedetomidine, the time on medication was up to 24 hours. The duration of study 
drug infusion was unspecified in the one study in which dexmedetomidine was not 
effective in preventing delirium. This study by Wanat and colleagues43 was a 
retrospective investigation which limits the generalizability of its results. The five studies 
reported in this cohort represent three randomized clinical trials and two retrospective 
investigations. All three of the randomized clinical trials showed superiority of 
dexmedetomidine when compared to morphine and propofol in reducing the incidence of 
postoperative delirium.  
 
 
39 
Mechanical Ventilation  
Standard management of sedation in the general ICU typically relies heavily on GABA 
receptor agonists such as propofol and benzodiazepines, such as midazolam and/or 
lorazepam.2,54,55 Mechanically ventilated patients not following a surgical procedure were 
evaluated in five studies (Pandharipande et al. 200915; Riker et al.40; Pandharipande et 
al. 201016; Shehabi et al.42; and Kawazoe et al.46). Delirium and coma-free days were 
decreased in three out of the five studies. In the two studies where the incidence of 
delirium was not reduced (Shehabi and Kawazoe), delirium was a secondary endpoint, 
thus these studies may not have been adequately powered to detect changes in the 
prevalence of delirium. The three studies in which dexmedetomidine was effective in 
reducing delirium consisted of two randomized clinical trials, and one retrospective 
cohort study. Therefore, additional research is needed to support the use of 
dexmedetomidine for sedation not following a surgical procedure.  
Aging 
Lastly, among the 16 studies, five studies specifically targeted adults aged 70 years and 
older (Shehabi et al.40; Djaiani et al.50; Cheng et al.45; Deiner et al52; and Su et al.51). The 
occurrence of delirium was reduced following usage of dexmedetomidine in four out of 
five studies. These studies included four randomized controlled trials with reduction of 
delirium as the primary outcome measure40,50-52 and one retrospective cohort analysis 
with delirium as a secondary outcome measure.45 This cohort also characterizes three 
cardiac surgical studies and two non-cardiac surgical studies. In each of the four studies 
in which delirium was reduced following administration of dexmedetomidine, it was 
administered in the postoperative setting. In the study by Deiner and colleagues,52 which 
did not report a statistically significant reduction in delirium, the drug was administered in 
the preoperative setting (these concerns have been discussed above). Taken together, 
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these outcomes support that the administration of dexmedetomidine is safe in older 
adults, often with the advantageous consequence of decreasing and/or preventing the 
development of delirium. Specifically, in older adults undergoing cardiac surgical 
procedures, there is compelling evidence to support postoperative sedation with 
dexmedetomidine may reduce the incidence of delirium.  
Gaps in the Research and Future Directions 
Patients included in the cardiac surgery subgroup were admitted to the cardiac ICU 
following some type of cardiac surgical procedure, whereas patients in the mechanically 
ventilated subgroup may not have undergone a surgical procedure (i.e. admitting 
diagnosis sepsis, pneumonia, shock, etc.). The cardiac surgery subgroup, therefore, 
reflects a more homogenous patient population as the procedures during and following 
cardiac surgery tend to be more routine. However, it also presents greater variability in 
study drug administration and is possibly confounded due to exposure to general 
anesthesia during surgery. Additionally, some studies used dexmedetomidine for 
sedation or prevention of delirium over a short time period. When given later on in the 
ICU course or for longer durations dexmedetomidine may not have the same effects. 
None of the studies included reports of non-pharmacological interventions as part of 
their reduction strategies. Recent evidence supports the promotion of sleep, aiming to 
provide at least 4 hours of sleep per night, for the reduction of delirium.56 Only one study 
included in this review evaluated patient’s quality of sleep. Pain management is another 
unaddressed concern in this evidence-based review. Only two of the 16 studies reported 
pain scores. The short-term consequences of undermanaged pain include higher energy 
expenditure and immunomodulation, both of which can contribute to the incidence of 
delirium. Sensory stimulation and early mobilization are other facets of the delirium 
prevention bundle that were not addressed in the articles included in this review.56 
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Unreported inclusion of some, or all, of these factors may have aided in reduction of 
delirium in the presented studies. The lack of this information makes it difficult to assess 
if these non-pharmacologic strategies, incorporated in many ICUs, played a role in the 
development of the results.  
An additional limitation of this work is the lack of studies using age as a control 
variable. As noted, the older adult population ( 65 years) is at the greatest risk for 
developing delirium. Also, there is no consensus on the duration and timing of drug 
administration. Additional studies are needed comparing the duration of infusion. In 
accordance with the hypothesis that dexmedetomidine may mimic natural sleep 
architecture, studies should also be completed to evaluate day-time versus nighttime 
drug administration. If sleep is a potential curative or preventative measure for reducing 
the incidence of delirium, nighttime administration of dexmedetomidine may be 
advantageous in aligning patients with their natural circadian rhythms to facilitate more 
restful and restorative sleep. This mechanism should be evaluated more thoroughly in 
randomized clinical studies.  
Conclusions  
At present, dexmedetomidine administration does not reduce the incidence and/or 
duration of delirium uniformly across all patient populations included in this review. 
However, there is good evidence to support the administration of dexmedetomidine 
during and following cardiac surgical procedures. This finding is in good agreement with 
the results of three recent meta-analysis in ICU patients.57-59 In future work, non-
pharmacologic interventions, pain management, and quality of sleep need to be included 
in these validation studies. Each of these capacities (pain management, sleep, drug 
administration) are area’s in which bedside care providers are important stakeholders 
and should help drive this research forward. As the population continues to age and the 
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incidence of comorbid illnesses grows, addressing the prevention and reduction of 
delirium is a timely and imperative objective.  
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Table 2.1 Johns Hopkins Evidence Level and Quality Guide 
Evidence Levels Quality Guides 
Level I  
Experimental study, randomized controlled 
trial (RCT) 
Systematic review of RCTs, with or without 
meta-analysis  
A High quality: Consistent, generalizable 
results; sufficient sample size for the 
study design; adequate control; 
definitive conclusions; consistent 
recommendations based on 
comprehensive literature review that 
includes thorough reference to scientific 
evidence 
 
B Good quality: Reasonably consistent 
results; sufficient sample size for the 
study design; some control, fairly 
definitive conclusions; reasonably 
consistent recommendations based on 
fairly comprehensive literature review 
that includes some reference to 
scientific evidence 
 
C Low quality or major flaws: Little 
evidence with inconsistent results; 
insufficient sample size for the study 
design; conclusions cannot be drawn 
Level II  
Quasi-experimental study 
Systematic review of a combination of RCTs 
and quasi-experimental, or quasi-experimental 
studies only, with or without meta-analysis 
Level III  
Non-experimental study 
Systematic review of a combination of RCTs, 
quasi-experimental and non-experimental 
studies, or non-experimental studies only, with 
or without meta-analysis 
Qualitative study or systematic review with or 
without a meta-synthesis 
Level IV  
Opinion of respected authorities and/or 
nationally recognized expert 
committees/consensus panels based on 
scientific evidence  
Includes: 
• Clinical practice guidelines 
• Consensus panels 
Level V  
Based on experiential and non-research 
evidence 
Includes: 
• Literature reviews 
• Quality improvement, program or financial 
evaluation 
• Case reports 
• Opinion of nationally recognized 
experts(s) based on experiential evidence 
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Table 2.2 Table of Evidence 
Authors/Year/ 
Country 
Study Aim Methodology, Study Design Sample Characteristics Major 
Findings/Outcomes 
Evidence 
Level and 
Grade 
Mechanical Ventilation 
Pandharipande 
et al.1 2007, 
United States 
Evaluate if 
dexmedetomidine 
reduces the duration 
of delirium and coma 
in mechanically 
ventilated ICU 
patients while 
providing adequate 
sedation as compared 
with lorazepam. 
Randomized, double-blind, controlled trial 
 
Patients were randomized upon arrival to the ICU. 
The study drug was infused as needed until 
extubation or for the maximum time allowed (120 
hours).  
 
Dexmedetomidine: 0.15 – 1.5 μg · kg-1 · h-1 
 
OR  
 
Lorazepam: 1 – 10 mg · h-1 
 
Delirium assessed using the CAM-ICU.  
Mechanically ventilated medical and 
surgical ICU patients at 2 tertiary 
care centers between August 2004 
and April 2006. 
 
Sample size: 106 
 
Age, Median (Interquartile Range) 
Dexmedetomidine 60 (49 - 65) 
Lorazepam 59 (45 - 67) 
Dexmedetomidine 
patients had more 
days alive without 
delirium or coma 
(median, 7 vs. 3; p = 
0.01) 
  
Level I 
Grade A  
Riker et al.2, 
2009, United 
States 
To compare the 
efficacy and safety of 
prolonged sedation 
with 
dexmedetomidine vs 
midazolam for 
mechanically 
ventilated patients. 
Prospective, randomized, double-blind, controlled 
trial  
 
Patients were randomized with in 96 hours of being 
intubated. The study drug was infused as needed 
until extubation, after a maximum of 30 days, or at 
the discretion of the investigator.  
 
Optional loading dose: 
Dexmedetomidine: up to 1.0 μg · kg-1  
 
OR  
 
Midazolam 0.05 mg · kg-1 
 
Maintenance Infusion Rate Midpoint:  
Dexmedetomidine: 0.8 μg · kg-1 · h-1 
 
OR  
 
Midazolam 0.06 mg · kg-1 · h-1  
 
Delirium assessed using the CAM-ICU. 
Medical/surgical ICU patients with 
expected mechanical ventilation for 
more than 24 hours. Conducted in 
68 centers in 5 countries between 
March 2005 and August 2007.  
 
Sample size: 375 
 
Age, mean (SD) 
Dexmedetomidine 61.5 (14.8) 
Midazolam 62.9 (16.8) 
Using a generalized 
estimating equation 
analysis, the effect of 
dexmedetomidine 
treatment on delirium 
was 24.9% reduction 
(95% CI; 16% - 34%, 
p <0.001).  
 
The prevalence of 
delirium was 54% 
(132/244) in 
dexmedetomidine 
treated patients vs. 
76.6% (93/122) in 
midazolam patients. 
(22.6% difference, 
95% CI; 14% to 33%, 
p > 0.001) 
 
Level I 
Grade A 
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Pandharipande 
et al.3, 2010, 
United States 
Evaluate if 
dexmedetomidine 
compared to 
lorazepam would 
provide greater 
improvements in 
clinical outcomes 
among septic patients 
than among non-
septic patients. 
Subgroup analysis of Pandharipande et al.1 in 
patients with and without sepsis identified within 48 
hours of enrollment.  
 
Patients were randomized upon arrival to the ICU. 
The study drug was infused as needed until 
extubation or for the maximum time allowed (120 
hours).  
 
Dexmedetomidine: 0.15 – 1.5 μg · kg-1 · h-1 
 
Delirium assessed using the CAM-ICU. 
Adult medical/surgical mechanically 
ventilated patients. 
 
Sample size: 103 
 
Age, Median (Interquartile Range) 
With Sepsis  
Dexmedetomidine 60 (46 - 65) 
Lorazepam 58 (44 -66) 
Without Sepsis  
Dexmedetomidine 61 (50 - 68) 
Lorazepam 60 (52-67) 
Septic patients 
sedated with 
dexmedetomidine 
had a mean (95% CI) 
of 3.2 (1.1 to 4.9) 
more delirium/coma 
free days than 
patients receiving 
lorazepam.  
 
However, no 
significant difference 
was seen between 
patients treated with 
dexmedetomidine 
and lorazepam in 
non-septic patients.  
 
Level III 
Grade B 
Shehabi et al.4, 
2013, Australia 
and New 
Zealand 
To assess the 
feasibility and safety 
of delivering early 
goal-directed sedation 
with 
dexmedetomidine 
compared with 
standard sedation 
with midazolam 
and/or propofol. 
Multicenter, prospective, open label, randomized 
controlled trial 
 
Patients were randomized within12 hours of arrival 
to the ICU or intubation. The study drug was 
infused as needed until sedation was no longer 
required or up to 28 days.  
 
Early Goal-Directed Sedation  
Dexmedetomidine: 0.1 – 1.5 μg · kg-1 · h-1  
 
Delirium assessed using the CAM-ICU. 
 
Critically ill adults mechanically 
ventilated for greater than 24 hours. 
 
Sample size: 37 
 
Age, mean (SD) 
Standard Sedation 61.6 (17) 
 
Early Goal-Directed Sedation 65 (15) 
 
An equal portion of 
patients experienced 
one or more positive 
CAM-ICU 
assessments during 
the study period 
(38%; p = 0.97).  
 
Level I 
Grade B 
 
Kawazoe et 
al.5, 2017, 
Japan 
To examine whether 
a sedation strategy 
with 
dexmedetomidine can 
improve clinical 
outcomes in patients 
with sepsis 
undergoing 
ventilation. 
 
Open-label, multicenter randomized clinical trial  
 
Study drug administration occurred upon ICU 
admission. The study drug was infused as needed 
until sedation was no longer required. 
 
Dexmedetomidine: 0.1 – 0.7 μg · kg-1 · h-1 
 
Delirium assessed using the CAM-ICU. 
 
 
 
 
Patients with sepsis requiring 
mechanical ventilation for at least 24 
hours. 
 
Sample size: 201 
 
Age, mean (SD) 
Dexmedetomidine 68 (14.9) 
Control Group 69 (13.6) 
The rate of delirium 
free days was not 
significantly different 
between groups (p = 
0.17). 
 
 
Level I  
Grade A 
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Cardiac Surgery 
Maldonado et 
al.6, 2009, 
United States 
Investigated the 
effects of 
postoperative 
sedation on the 
development of 
delirium in patients 
undergoing cardiac-
valve procedures. 
Randomized, open-label, controlled trial 
 
After successful weaning from CPB, patients were 
started on one of three randomly assigned, 
postoperative sedation regimens. Patients were 
extubated while still on the medication and were 
kept on the maintenance infusion as deemed 
clinically necessary for a maximum of 24 hours. 
 
Loading dose: 
Dexmedetomidine: 0.4 μg · kg-1  
 
Infusion Rate:  
Dexmedetomidine: 0.2 – 0.7 μg · kg-1 · h-1 
 
OR 
 
Propofol: 25 – 50 g · kg-1 · m-1  
 
OR 
 
Midazolam: 0.5 – 2.0 mg · h-1 
Delirium assessed by a trained neuropsychiatrist. 
Patients schedule for elective 
cardiac valve operations.  
 
Sample size: 118 
 
Age, mean (SD) 
Dexmedetomidine 55 (16)  
Propofol 58 (18)  
Midazolam 60 (16)  
Using a per-protocol 
analysis, the 
incidence of delirium 
for patients receiving 
dexmedetomidine 
was 3% (1/30); 
propofol 50% (15/30); 
and midazolam 50% 
(15/30).  
 
  
Level I 
Grade A 
Shehabi et al.7, 
2009, Australia 
and New 
Zealand 
To assess the 
neurobehavioral, 
hemodynamic, and 
sedative 
characteristics of 
dexmedetomidine 
compared with 
morphine-based 
regimen after cardiac 
surgery at equivalent 
levels of sedation and 
analgesia. 
Randomized, double-blind, controlled trial 
 
Study drug infusions were started in the ICU. The 
infusion was continued until the removal of chest 
drains, when patient was ready to discharge from 
ICU, or for up to 48 hours of mechanical 
ventilation. 
 
Dexmedetomidine: 0.1 – 0.7 μg · kg-1 · h-1  
 
OR 
 
Morphine: 10–70 g · kg-1 · ml-1  
 
Delirium assessed using the CAM-ICU. 
Cardiac surgery patients 60 years of 
age or older. Conducted in two 
tertiary university affiliated hospitals 
between 2004 and 2007.  
 
Sample size: 306 
 
Age, Median (Interquartile Range) 
Dexmedetomidine 71.5 (66 – 76) 
Morphine 71(65 – 75) 
The overall incidence 
of delirium within 5 
days was 11.7% (35 
of 299) with 8.6% 
occurring in the 
dexmedetomidine 
group and 15% 
occurring in the 
morphine group (RR 
0.571, 95% CI 0.256-
1.099, p = 0.088).  
Level I 
Grade A 
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Fuhai et al.8, 
2013, United 
States  
To determine whether 
the perioperative use 
of dexmedetomidine 
could reduce the 
incidence of 
complications and 
mortality after cardiac 
surgery 
Retrospective cohort study 
 
Perioperative dexmedetomidine was administered 
after CPB and continued for less than 24 hours 
postoperatively in the ICU. 
 
Dexmedetomidine: 0.24 – 0.6 μg · kg-1 · h-1  
 
Delirium was assessed by the presence of 
illusions, confusion, cerebral excitement having a 
comparatively short course.  
Patients who underwent coronary 
artery bypass surgery and coronary 
artery bypass or other cardiac 
procedures were included. 
 
Sample size: 1134 
 
Age, mean (SD) 
Dexmedetomidine 63 (12)  
Non-dexmedetomidine 63.5 (11) 
The multivariate 
model assessing 
delirium (5.46% 
versus 7.42%; 
adjusted odds ratio, 
0.53; 95% confidence 
interval, 0.37–0.75; p 
= 0.0030) was 
statistically significant 
between the 
dexmedetomidine 
and non-
dexmedetomidine 
groups. 
 
 
Level III 
Grade B 
Fuhai et al.9, 
2014, United 
States 
This study 
retrospectively 
investigated the effect 
of dexmedetomidine 
on outcomes of 
patients undergoing 
coronary artery 
bypass graft (CABG) 
surgery. 
 
Retrospective cohort study 
 
Perioperative dexmedetomidine was administered 
after CPB and continued for less than 24 hours 
postoperatively in the ICU. 
 
Dexmedetomidine: 0.24 – 0.6 μg · kg-1 · h-1  
 
Delirium was assessed by the presence of 
illusions, confusion, cerebral excitement having a 
comparatively short course.  
 
Patients undergoing CABG surgery. 
 
Sample size: 724 
 
Age, mean (SD) 
Dexmedetomidine 62.9 (11.8)  
Non-dexmedetomidine 64.1 (11.4) 
The adjusted rates of 
delirium (adjusted 
OR, 0.431; 95% CI, 
0.265 to 0.701, p = 
0.0007) were 
statistically significant 
between the 
dexmedetomidine 
and non-
dexmedetomidine 
groups.  
 
 
Level III 
Grade B 
Wanat et al.10, 
2014, United 
States 
Comparison of 
dexmedetomidine 
versus propofol for 
sedation in 
mechanically 
ventilated patients 
after cardiovascular 
surgery 
Retrospective cohort study 
 
Sedation orders were based on individual 
physician ordering upon arrival to the ICU.  
 
Average Dose  
Dexmedetomidine: 0.489  0.13 μg · kg-1 · h-1  
 
Delirium assessed using the CAM-ICU. 
 
Patients admitted to the ICU after 
cardiovascular surgery from January 
through June 2011. 
 
Sample size: 352 
 
Age, mean (SD) 
Dexmedetomidine 63 (14.1) 
Propofol 68 (11.2)  
CAM-ICU scores 
were reported in 79% 
of dexmedetomidine 
patients and 84% of 
propofol patients (p = 
0.411). Incidence of 
delirium (any vs. 
none) was similar 
between both groups 
(9.09% vs. 7.52%, p = 
0.747). 
 
Level III 
Grade B 
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Cheng et al.11, 
2016, United 
States 
The goal of this 
retrospective study 
was to investigate the 
effects of 
perioperative use of 
dexmedetomidine on 
outcomes for older 
patients undergoing 
cardiac surgery. 
Retrospective cohort study 
 
Drug infusion was initiated after CBP and 
continued for 24 hours postoperatively in the ICU. 
 
Dexmedetomidine: 0.24 – 0.6 μg · kg-1 · h-1  
 
Delirium was assessed by the presence of 
illusions, confusion, cerebral excitement having a 
comparatively short course.  
Patients underwent coronary artery 
bypass graft (CABG) or valve 
surgery. 
 
Sample size: 505 
 
Age, mean (SD) 
Dexmedetomidine 73.6 (6.1)  
Non-dexmedetomidine 73.5 (6.2) 
Results of 
multivariate analysis 
show that 
postoperative delirium 
(adjusted OR, 0.350; 
95% CI, 0.212-0.578; 
p = 0.007) was 
decreased 
significantly in the 
dexmedetomidine 
group.  
Level III 
Grade B 
Djaiani et al.12, 
2016, Canada 
Dexmedetomidine 
sedation after cardiac 
surgery would reduce 
the incidence of 
postoperative delirium 
Single-blind, prospective, randomized controlled 
trial  
 
Upon arrival to ICU sedation was initiated. The 
infusion was continued for a maximum period 
of 24 hours.  
 
Loading dose: 
Dexmedetomidine: 0.4 μg · kg-1  
 
Infusion Rate:  
Dexmedetomidine: 0.2 – 0.7 μg · kg-1 · h-1 
 
OR 
 
Propofol: 25 - 50 μg · kg-1 · m-1 
 
Delirium assessed using the CAM-ICU. 
Patients undergoing cardiac surgery. 
 
Sample size: 185 
 
Age, mean (SD) 
Dexmedetomidine 72.7 (6.4)  
Propofol 72.4 (6.2)  
A total of 11 (12.1%) 
and 25 (27.1%) in the 
dexmedetomidine 
and propofol groups 
respectively, 
developed delirium.  
 
Level I 
Grade B 
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Li et al.13, 2017, 
China  
The purpose of this 
study was to 
investigate the impact 
of perioperative 
dexmedetomidine 
administration on the 
incidence of delirium 
in elderly patients 
after cardiac surgery. 
 
Randomized, double-blind, placebo-controlled trial 
 
In the operating room, study drug infusion was 
started once the intravenous access was 
established until the end of surgery. After surgery, 
study drug infusion was continued until the end of 
mechanical ventilation. 
 
Loading dose: 
Dexmedetomidine: 0.6 μg · kg-1  
 
Infusion Rate During Surgery:  
Dexmedetomidine: 0.4 μg · kg-1 · h-1 
 
Infusion Rate Post-Operatively:  
Dexmedetomidine: 0.1 μg · kg-1 · h-1 
 
Delirium assessed using the CAM-ICU. 
 
 
Patients after cardiac surgery. 
 
Sample size: 285 
 
Age, mean (SD) 
Dexmedetomidine 66.4 (5.4)  
Control Group 67.5 (5.3)  
There was no 
significant difference 
between the two 
groups in the 
development of 
delirium during the 
first 5 days following 
surgery, 4.9% (7/142) 
in the 
dexmedetomidine 
group vs 7.7% 
(11/143) in the control 
group (OR; 0.62, 95% 
CI 0.23-1.65; p = 
0.341) 
Level I  
Grade A 
Non-Cardiac Surgery 
Yang et al.14, 
2015, China 
To determine whether 
dexmedetomidine 
sedation in the post-
anesthesia care unit 
could decrease 
agitation and delirium 
after free flap surgery 
Prospective, randomized, double-blind, controlled 
trial 
 
Infusion of the blinded study drug was started 
approximately 60 minutes before the end of 
surgery until the operation was completed; 
infusions were continued in the PACU until 6:00 
AM the next morning.  
 
Infusion Rate During Surgery:  
Dexmedetomidine: 0.5 μg · kg-1 · h-1 
 
Infusion Rate Post-Operatively:  
Dexmedetomidine: 0.2 – 0.7 μg · kg-1 · h-1 
 
OR 
 
0.9% Saline 
 
Delirium assessed using the CAM-ICU. 
  
Patients scheduled for maxillofacial 
surgery from June to October 2013. 
 
Sample size: 80 
 
Age, mean (SD) 
Dexmedetomidine 50.3 (15)  
Control group 50.6 (12.3)  
The incidence of 
delirium within 5 days 
postoperatively was 
similar between the 
dexmedetomidine 
(5.1%; 2 of 39 
patients) and control 
(saline) groups 
(12.5%; 5 of 40 
patients; p = 0.432)  
Level I 
Grade A 
Su et al.15, 
2016, China  
To investigate 
whether prophylactic 
Randomized, double-blind, placebo-controlled trial  
 
Patients admitted to intensive care 
units after non-cardiac surgery. 
Post-operative 
delirium occurred in 
Level I  
Grade A 
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low-dose 
dexmedetomidine 
could safely decrease 
the incidence of 
delirium in elderly 
patients after non-
cardiac surgery.  
Infusion was started from study recruitment on the 
day of surgery (usually within 1 hour after ICU 
admission) until 0800 h on the first day after 
surgery. 
 
Dexmedetomidine: 0.1 μg · kg-1 · h-1 
 
OR 
 
0.9% Normal Saline  
 
Delirium assessed using the CAM-ICU. 
 
Sample size: 700 
 
Age, mean (SD) 
Dexmedetomidine 74.3 (6.7)  
Control group 74.4 (7.0) 
79 (23%) of patients 
receiving placebo, 
and in 32 (9%) of 
patients receiving 
dexmedetomidine 
(OR, 0.35, 95% CI 
0.22 – 0.54; p = 
<0.0001) 
Deiner et al.16, 
2017, United 
States 
To evaluate whether 
an intraoperative 
infusion of 
dexmedetomidine 
reduces postoperative 
delirium. 
Multicenter, double-blind, randomized, placebo-
controlled trial 
 
Infusions were started in patients on entering the 
operating room and was continued until 2 hours 
into recovery. 
 
Dexmedetomidine: 0.5 μg · kg-1 · h-1 
 
OR  
 
0.9 % Saline 
 
Delirium assessed using the CAM-ICU. 
Patients undergoing major elective 
non-cardiac surgery. 
 
Sample size: 404 
 
Age, Median (Interquartile Range) 
Dexmedetomidine 74 (71-78)  
Control group 74 (71-78) 
In total 12.2% (23 of 
189) of patients who 
received 
dexmedetomidine 
and 11.4% (23 of 
201) of patients who 
received placebo 
experienced delirium.  
  
Level I  
Grade A 
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Chapter 3  
Evaluating a nurse-led intervention for delirium among older adults in the surgical 
intensive care unit 
Abstract 
Background. Delirium, a prevalent condition in hospitalized older adults ( 65 years), is 
an acute brain dysfunction characterized by disturbances in attention, awareness and 
cognition not explained by a pre-existing neurocognitive disorder. The ICU Liberation 
Executing the ABCDEF Bundle Daily (iLEAD) is a nurse-driven protocol aimed at 
reducing the severity of delirium in the surgical intensive care unit (SICU) via the 
implementation of independent nursing interventions.  
Objectives. When nurses routinely assess and manage modifiable risk factors for 
delirium (pain; sensory impairment; immobilization; medication administration; surgery, 
environment; emotional distress; and sustained sleep deprivation), the number of days 
of delirium will decrease and patient outcomes will improve. This retrospective analysis 
evaluated the impact of the iLEAD intervention on the number of days with delirium, 
length of stay in the SICU, overall hospital length of stay, 30-day readmission rates and 
30-day mortality experienced by older adults. 
Methods. Employing an observational cohort design, this study compared delirium 
outcomes pre- versus post-iLEAD implementation. The sample consisted of 93 patients 
admitted to the SICU at the Hospital of the University of Pennsylvania. Outcomes were 
evaluated by medical record review.  
Results. Rates of delirium screening more than doubled following iLEAD 
implementation. Consistent with previous reports, delirium contributed to both SICU and 
overall hospital length of stay and 30-day mortality. Other than a trend for improvements 
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in rates of 30-day readmissions, no improvement in delirium outcomes were noted for 
the patients who received iLEAD delirium-informed care. 
Conclusions. This work examined the nurse-management of delirium among older adult 
patients admitted to the SICU. Improved patient outcomes, while not statistically 
significant, were achievable in the early stages of the iLEAD intervention and may inform 
prospective systems-level organizational change. With continued adherence to the 
iLEAD intervention, it is hypothesized that outcomes will progressively improve.  
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Introduction  
Delirium is an acute brain dysfunction characterized by disturbances in attention, 
awareness and cognition not explained by a pre-existing neurocognitive disorder.1 
Delirium in the intensive care unit (ICU) is common for hospitalized older adult patients 
( 65 years) due to the severity of their illnesses, the number of their comorbidities and 
their advanced age,1-3 and has been reported to occur in approximately 50% of all 
hospitalized older adults.2 The clinical presentation of delirium can be hypoactive, 
hyperactive or mixed.1 Notably, the hypoactive form occurs most frequently in older adult 
patients, and too often, these patients are overlooked or misdiagnosed as having 
depression or dementia as opposed to delirium.2 Aging itself has also been described as 
a risk factor for developing delirium.4-7  
Older adults consume nearly 60% of all ICU days8 and are predisposed to higher 
rates of delirium than adults under the age of 65 years. For these older adults, delirium 
poses a significant health threat.3,5,9,10 Delirium has been associated with longer ICU and 
hospital stays,9,11-13 increased health care costs and poorer outcomes related to 
readmissions14-16 and increased mortality.9,12,17-19 Delirium has been identified as one of 
six leading causes of injuries associated with hospitalization in older adults.20 
In a study of 304 older adult patients admitted to the medical ICU, the typical length 
of ICU stay was five days, with an average of three days of delirium.12 Added costs per 
hospitalization attributable to delirium range from $16,303 to $64,421 per patient.14 A 
one-year study of hospitalized adults 70 years or older, reported 109 patients (13.0%) 
developed delirium while 732 did not.15 The subsequent health care costs associated 
with delirium suggested that patients with delirium were more than 2.5 times as costly 
than patients without delirium.15 In that Medicare and Medicaid reimbursements are tied 
to rates of 30-day readmissions,21 some delirium-related costs are attributed to 
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readmitted patients with delirium. Readmissions alone also have also been associated 
with unfavorable patient outcomes in patients with delirium.16 Finally, delirium has been 
reported to be an independent marker for increased mortality in older medical inpatients 
both 6- and 12-months after hospital admission.9,18 Because delirium can be a life-
threatening condition for older adults,2 limiting its occurrence and severity is imperative 
to improving patient outcomes. To date, there are few studies that have specifically 
examined the effect of delirium on outcomes of older adults admitted to the surgical 
intensive care unit (SICU).  
The 2013 revised Society for Critical Care Medicine (SCCM) Clinical Practice 
Guidelines for Management of Pain, Agitation, and Delirium22 recommend routine 
monitoring of sedation, pain and delirium for all patients in the ICU. The SCCM’s ICU 
Liberation Collaborative initiative offers a broad program to enable the application of 
these guidelines across hospital systems.23-26 ICU Liberation uses a set of interventions 
known as the “ABCDEF Bundle” to guide execution of their recommendations. The 
elements of ABCDEF bundle individually and collectively aim to reduce delirium, pain, 
agitation and the long-term negative health consequences of delirium in adult ICU 
patients.24,25,27,28 The first large scale evaluation of the ABCDEF bundle included over 
15,000 adult patients (18+ years of age) from 68 ICUs (including mixed medical/surgical, 
medical, surgical/trauma, neurological, cardiac/surgical and surgical). Complete 
performance of the ABCDEF bundle was associated with a lower likelihood of next-day 
mechanical ventilation, decreased rates of delirium, reduced ICU readmissions and 
decreased 7-day mortality rates.26 
Utilizing the principles of systems science, which encompass improving quality, 
outcomes, and costs of health care delivery for patients and populations within systems 
of medical care,29 The Hospital of the University of Pennsylvania created the ICU 
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Liberation Executing the ABCDEF Bundle Daily (iLEAD), a nurse-driven intervention 
designed by an interprofessional team to implement the ABCDEF bundle and reduce the 
consequences of delirium in the ICU within their health system. A study was undertaken 
to compare (1) days of delirium, (2) SICU and (3) hospital length of stay, (4) 30-day 
readmission rates and (5) 30-day mortality in cohorts of older adults in the SICU prior to 
and following implementation of the iLEAD intervention. A conceptual model (Figure 3.1) 
illustrates the relationships of risk factors outlined in the iLEAD protocol for delirium to 
the clinical outcomes of interest. It is postulated that the assessment of non-modifiable 
risks for delirium and management of modifiable risks will lead to fewer days of delirium 
and improved patient outcomes. When nurses routinely assessed and managed 
modifiable risk factors for delirium (i.e., implement the iLEAD intervention), it was 
hypothesized that patient outcomes would improve.  
Methods 
Design  
A retrospective observational pre- and post-intervention cohort study was designed to 
examine delirium-related outcomes in older adult patients in the SICU which might have 
contaminated the care received prior to formal implementation. All data were extracted 
from the electronic health record (EHR). The primary patient outcomes of this 
investigation were: days of delirium; SICU length of stay in days; hospital length of stay 
in days; rates of 30-day readmissions and rates of 30-day mortality. The study was 
approved by the University of Pennsylvania Institutional Review Board with exempt 
status and waiver of informed consent. Study design and reporting conformed with 
criteria outlined in the STrengthening the Reporting of OBservational studies in 
Epidemiology (STROBE) guidelines.30  
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Setting and Sample 
Study participants were selected from a 24-bed surgical critical care unit at a 795-bed 
urban academic medical center. Consecutive patients 65 years or older admitted to the 
SICU between March 15 and August 15, 2017 were screened for inclusion in the pre-
iLEAD implementation cohort. These patients were compared to a similar cohort of 
patients admitted to the same SICU between March 15 to August 15, 2018, representing 
the post-iLEAD implementation cohort. The iLEAD intervention was implemented in 
January 2018. These cohorts were intentionally selected with several factors in mind. 
First, the two cohorts were sampled during the same 6-month calendar periods, 
accounting for differences in SICU admission by time of year. Second, March was 
chosen as the start date to reflect sufficient duration from the start of the iLEAD 
implementation in January, so compliance rates to the intervention would be sufficiently 
high. The pre-iLEAD intervention cohort were admitted before any iLEAD planning or 
education occurred. During the post-implementation cohort study period, the 
interventions for Awake and pain free, spontaneous Breathing trials, Consideration of 
Analgesia and Sedation and Delirium were fully implemented, however interventions for 
Exercise and Family engagement were still being introduced to the nursing workflow. 
Inclusion criteria were; age  65, English speaking, admitted to the SICU for >24 
hours, and having screened positive for delirium during the first seven days of ICU stay. 
Patients were excluded if they had an admitting diagnosis related to neurological or 
central nervous system injury; for patients readmitted to the SICU, only the index 
admission was evaluated. Patients not evaluated for delirium using the confusion 
assessment method for the intensive care unit (CAM-ICU) between day 1 and day 7 
during their admission to the SICU were also excluded. As illustrated in Figure 3.2, the 
pre-implementation 2017 sampling pool contained 101 patients, and the post-
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implementation 2018 sampling pool, 172 patients. Of the total sample, 37 and 56 
patients screened positive for delirium in the 2017 and 2018 cohorts respectively.  
Intervention 
The iLEAD intervention is a nurse-driven protocol aimed at reducing delirium in the ICU. 
As described above, it incorporates a set of interventions designed to coordinate care, 
with a specific focus on delirium, as a component of the overall care patients receive.25 
Specifically, upon admission to the SICU, the nursing staff reviewed a patient’s medical 
history for relevant delirium risk factors (age, history of cognitive impairment, immobility, 
audio or visual impairments, history of alcohol use, history of delirium, etc.). Delirium 
assessments (CAM-ICU) were conducted twice daily (AM and PM) beginning upon 
admission. Patients with a positive CAM-ICU assessment were evaluated for new 
infections, or cardiac or neurological events that may explain the change in their mental 
status. Inpatient and home medications were also reviewed to assess for medications 
likely to induce delirium, such as opioids and benzodiazepines. For those patients who 
screened positive for delirium, nurses initiated at least two independent non-
pharmacological interventions selected from a menu of interventions based on the risk 
factors identified. Additional engagement with the interdisciplinary team was utilized to 
identify possible causes of delirium and treatment approach. Delirium was continually 
reassessed with the CAM-ICU every 12 hours to monitor for response to the 
interventions. 
Measures  
Delirium. The primary study outcome was the number of days of delirium calculated 
using the highly reliable and well-validated CAM-ICU assessment tool.31-33 Reliability for 
the CAM-ICU has been established against the DSM-V diagnostic criteria for delirium 
(interrater reliability kappa = 0.79-0.96).31 Compared with a reference standard 
 
 
64 
(psychiatrist) diagnosis of delirium, the CAM-ICU used by nursing staff had sensitivity 
estimates of 93-100% and specificity of 89-100%.31 The CAM-ICU recognizes delirium 
based on four features: 1) acute onset of mental status changes or a fluctuating course; 
2) inattention; 3) disorganized thinking; and 4) altered level of consciousness.32,33 For 
delirium to be scored as present, a patient must display both a change in mental status 
and inattention, along with either disorganized thinking or altered level of 
consciousness.32,33 The CAM-ICU was completed and scored by trained nursing staff 
every 12 hours. Each assessment generated one of four possible results; positive, 
negative, unable to assess (comatose), or no test performed. One day of “no delirium” 
was defined as either two negative CAM-ICU assessments, or one negative and one 
unable to assess evaluation in a 24-hour period. One day of “delirium” was defined as 
one positive CAM-ICU screening in a 24-hour period. The number of days of at least one 
positive CAM-ICU screen were calculated beginning at the time of SICU admission 
through SICU discharge or up to 7 days. Delirium that emerges beyond 7 days may be 
related to an underlying medical abnormality or complications, and therefore not 
representative of ICU delirium.34,35  
Length of SICU Stay. SICU length of stay was calculated beginning at the time a 
patient was admitted to the SICU until they left the SICU.  
Length of Hospital Stay. Hospital length of stay was measured beginning at hospital 
admission until discharge.  
30-day Readmission Rates. Readmission rates were counted as being readmitted to 
the hospital for any cause within the 30 days after discharge from a hospitalization. Due 
to the limitations of the Penn Medicine EHRs, only readmissions to in-system hospitals 
are captured. 
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30-day Mortality Rates. Mortality rates were counted as a death occurring within 30 
days of hospital admission; deaths could be for any cause and occur in the hospital or 
after discharge. 
We also used the EHR to ascertain clinical and demographic data that were used as 
covariates. These included age, sex, race, use and duration of mechanical ventilation, 
Richmond Agitation-Sedation Scale (RASS) scores, and admitting medical diagnosis. 
Admitting diagnoses were utilized as a proxy measure for severity of illness. 
Data Analysis 
Descriptive statistics (mean, standard deviation, median, range and percentages) were 
produced to describe and compare sample characteristics of the pre- and post-
implementation cohorts using Student’s t-tests for independent groups for continuous 
variables and chi-square (𝜒2) tests for categorical variables. Fisher’s exact test was used 
for assessment of categorical variables where the cell counts were less than 5. Data 
were closely examined for any systematic patterns of missingness. P-values of 0.05 or 
less were considered to indicate statistical significance.  
Cox Proportional Hazards Regression models were conducted using the PHREG 
procedure in SAS to assess cohort (study year) as a predictor of SICU and hospital 
length of stay while accounting for both censored and non-censored data. The PHREG 
procedure is widely used in analyzing the effect of explanatory variables on time-to-
event variables. Patients who died during their SICU stay or had a SICU stay longer than 
30 days were classified as censored observations, indicating that they are not assessed 
as a true SICU discharge event. Similarly, patients who died during their hospital stay or 
had a hospital stay longer than 60 days were classified as censored observations. 
Analyses were adjusted for age, sex, race, RASS, use of mechanical ventilation and 
admitting diagnosis. The four most prevalent admitting diagnosis were included as 
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covariates (neoplasms, diseases of circulatory system, diseases of digestive system and 
symptoms, signs & abnormal labs) to control for the effects of medical condition on the 
efficacy of the intervention. Kaplan-Meier survival curves were produced for graphical 
presentation of these time-to-event analyses. As a preliminary assessment, Cox 
Proportional Hazards Regression models were also used to compare SICU and hospital 
length of stay between patients with and without delirium across both study years. 
Chi square tests were used to evaluate the association between cohort (study year) 
and 30-day readmissions, as well as 30-day mortality. Adjusted logistic regression 
analyses were then conducted and included age, sex, race, RASS, use of mechanical 
ventilation and admitting diagnosis as covariates. As a preliminary assessment, chi 
square tests were used to compare readmission and mortality rates between patients 
with and without delirium across both study years. 
Results 
In total, 653 patients were admitted to the SICU between March 15 and August 15, 2017 
and 630 patients were admitted between March 15 and August 15, 2018. After screening 
for inclusion and exclusion criteria, 101 patients in 2017 and 172 patients in 2018 were 
evaluated; of these, 37 patients in 2017 and 56 patients in 2018 screened positive for 
delirium, thus comprised the pre- and post-implementation cohorts. Demographically, 
the cohorts were comparable (Table 3.1) with the exception that patients with delirium in 
the 2018 cohort received more hours of mechanical ventilation during their SICU stay (p 
= 0.032).  
Outcomes of Patients with and without Delirium 
To validate previously described consequences of delirium, preliminary assessments 
were performed to compare patients with and without delirium in each cohort. As 
expected, Figure 3.3 reflects poorer outcomes for patients with delirium compared those 
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without delirium. The results were unchanged in the adjusted models. The unadjusted 
preliminary models are described as follows:  
SICU Length of Stay. In both cohorts (Figure 3.3, A and B), delirium exhibited a strong 
association with SICU length of stay (2017 𝜒2 = 21.1942, Hazard Ratio (HR): 0.394, p < 
0.0001: 2018 𝜒2 = 40.3134, HR: 0.316, p < 0.0001). Three patients in 2017 and eight 
patients in 2018 were censored due to either death or a SICU stay longer than 30 days.  
Hospital Length of Stay. Similarly, delirium exhibited a strong association with overall 
hospital length of stay (Figure 3.3, C and D) in 2017 (𝜒2 = 4.2657, HR: 0.649, p = 
0.0389) and 2018 (𝜒2 = 26.2117, HR: 0.436, p < 0.0001). Eight patients in 2017 and 15 
patients in 2018 were censored due to either death or a hospital stay of longer than 60 
days.  
Readmissions. No association between delirium and 30-day readmissions in 2017 (𝜒2 = 
0.0004, p = 0.9833) or 2018 (𝜒2 = 0.0076, p = 0.9304) were noted (Figure 3.3, E). Of 
patients with delirium in 2017, 18.92% were readmitted within 30 days of hospital 
admission compared to 18.75% of patients without delirium. In 2018, 14.29% of patients 
with delirium were readmitted within 30 days of hospital admission, compared to 13.79% 
of patients without delirium.  
Mortality. With respect to 30-day mortality (Figure 3.3, F), in 2017, 16.22% of patients 
with delirium died within 30 days of hospital admission, compared to 3.13% of patients 
without delirium (𝜒2 = 5.5092, p = 0.0189). In 2018, 16.07% of patients with delirium died 
within 30 days of hospital admission, compared to just 3.45% of patients without delirium 
(𝜒2 = 8.6133, p = 0.0033).  
Summary of CAM-ICU Assessments 
To illustrate adherence to the iLEAD intervention, the daily results of the CAM-ICU 
assessments were evaluated (Table 3.2). The number of days with a positive CAM-ICU 
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assessment was similar between the 2017 and 2018 cohorts (p = 0.7200). Notably, the 
number of days of a negative CAM-ICU assessment (p = 0.0178) and the number of 
days where no test was performed (p < 0.001) were statistically different between study 
year, reflecting the nurse’s uptake of the iLEAD intervention. The number of days with 
coma (p = 0.8873) remained similar between cohorts. 
Days of Delirium 
The incidence of delirium (37% vs. 33%, p = 0.511) and the average number of days of 
delirium (p = 0.1660) did not vary significantly by study year (Table 3.1).  
SICU Length of Stay 
Pre-iLEAD implementation, the median length of stay in the SICU for patients with 
delirium was 7 days compared to 8 days for patients following iLEAD implementation (p  
= 0.7499) (Table 3.1). Among the 2017 cohort, 51.35% of patients with delirium had 
been discharged from the SICU by one week, compared to 43.39% among the 2018 
cohort. Within the 2017 cohort, 96.29% of patients with delirium had been discharged 
from the SICU after 30 days, compared to 100% in the 2018 cohort (Figure 3.4, A). 
Study year was not found to be a significant predictor of SICU length of stay (𝜒2 = 
0.3403, HR: 0.881, p = 0.5597). After adjusting for covariates of interest, study year 
remained a nonsignificant predictor of SICU length of stay (𝜒2 = 1.6655, HR: 0.770, p = 
0.1969). 
Hospital Length of Stay  
For patients with delirium, the median length of stay in hospital was 15 days in 2017 
compared to 17.5 days for patients in 2018 (p = 0.1909) (Table 3.1). Among the 2017 
cohort, 13.51% of patients had been discharged after one week, compared to just 1.77% 
of patients in the 2018 cohort. After 30 days, 79.76% of the 2017 cohort had been 
discharged, compared to 59.98% in the 2018 cohort (Figure 3.4, B). Study year was not 
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found to be a significant predictor of hospital length of stay (𝜒2 = 2.299, HR: 0.695, p = 
0.1294). After adjusting for covariates of interest, study year was significant predictor of 
hospital length of stay (𝜒2 = 4.4103, HR: 0.618, p = 0.0357) favoring the 2017 cohort. 
30-day Readmissions 
In the 2017 cohort, 18.92% of patients with delirium were readmitted within 30 days of 
hospital admission compared to 14.29% in the 2018 cohort. Despite this trend for 
decreased 30-day readmissions (Figure 3.4, C), study year did not exhibit a significant 
association with hospital readmission (𝜒2 = 0.3535, p = 0.5521). After adjusting for 
covariates of interest, study year remained not a significant predictor of readmission 
rates (𝜒2 = 0.12, p = 0.7336).  
30-day Mortality  
Rates of 30-day mortality were essentially unchanged following the iLEAD intervention; 
in the 2017 cohort, 16.22% of patients with delirium died within 30 days of hospital 
admission, compared to 16.07% in the 2018 cohort (Figure 3.4, C). Study year did not 
exhibit a significant association with 30-day mortality (𝜒2 = 0.0003, p = 0.9852). Similarly, 
after adjusting for covariates of interest, study year was not a significant predictor of 
readmission rates (𝜒2 = 0.23, p = 0.6289). 
Discussion  
Delirium is a significant and costly problem for older adults in the ICU. It is commonly 
under-recognized and undertreated, and the consequences are not only evident in 
length of ICU and hospital stay, but in the more worrisome outcomes of 30-day 
readmissions and mortality. Empirical evidence for independent nurse-led interventions 
to mitigate the development and duration of delirium is accumulating and this evaluation 
of the iLEAD intervention contributes to this body of knowledge. In this study, patient-
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level outcomes attributable to delirium in older adults admitted to the SICU were 
examined prior to and following the implementation of the iLEAD intervention.  
These data support that delirium contributes to both SICU and overall hospital length 
of stay, and to 30-day mortality in older patients admitted to the SICU. No differences in 
30-day hospital readmission rates were observed in this sample between those with and 
without delirium. Increased ICU length of stay was previously reported in a prospective 
cohort study of 261 patients admitted to the medical ICU in which 125 patients (48%) 
experienced at least one episode of delirium. Patients who experienced delirium had a 
29% greater risk of remaining in the ICU (compared to patients who never developed 
delirium) even after adjusting covariates (HR: 1.29; CI: 0.98-1.69, p = 0.07).36 A similar 
study performed to determine the effects of delirium on length of hospital stay, 
concluded in-hospital delirium (36 of 359 patients) was an important predictor of longer 
hospital stay. The median length of stay for patients with delirium was 16.5 days 
compared to 7.5 days for patients without delirium (difference 9 days).37 With respect to 
mortality, a cohort study of 275 mechanically ventilated patients concluded that 50% of 
patients who experienced delirium during their ICU stay died within one-year post-
hospitalization,9 supporting similar studies that reported increased mortality following an 
episode of deliruim.12,18 The SCCM ICU Liberation Collaborative also reported that 
implementation of the ABCDEF bundle was associated with a decreased rates of 
delirium and a lower likelihood of 7-day mortality.26  
The unchanged 30-day hospital readmission rates observed in this study were 
somewhat surprising in that the literature has supported an association between delirium 
and hospital readmissions. For example, Eide and colleagues examined 136 patients 
aged 80 years or greater and evaluated the influence of delirium on 30-day readmission 
rates in patients undergoing cardiac surgery. Delirium was identified in 76 (56%) 
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patients; 24 out of 30 (80%) patients who were readmitted within 30 days experienced 
delirium.17 The lack of group differences in 30-day readmission rates in this sample may 
be explained by other factors such as severity of illness, or complications of the disease 
process, and not delirium.  
No improvement in delirium outcomes were noted for the cohort of patients who 
received iLEAD delirium-informed care, other than a trend for improvements in rates of 
30-day readmissions (from approximately 19% in 2017 to 14% in 2018). There are 
several potential reasons why the iLEAD intervention did not demonstrate effectiveness. 
Delirium was more frequently identified in the post-implementation cohort, and therefore 
the poor outcomes associated with delirium were more likely to be detected, potentially 
confounding the effect of the iLEAD intervention. While the typology of delirium was not 
captured in this study, patients with hyperactive delirium exhibit restlessness and 
agitation whereas those with hypoactive delirium generally present as lethargic or 
sedated and respond slowly to questions or show little spontaneous movements. It is 
possible that the primary subtype of delirium reported in the pre-implementation cohort 
was mainly hyperactive, as this type of delirium is readily visible as compared to 
hypoactive delirium which is more difficult to detect and more common in older adults.  
Consequently, while the iLEAD intervention did not show decreased length of stay 
for patients with delirium in the post-implementation cohort, patients with delirium in the 
pre-implementation cohort may have been more likely to be discharged before complete 
recovery from delirium due to lack of education and training. Increased detection rates 
for hypoactive delirium in the post-implementation cohort likely contributed to the 
increased SICU length of stay. Literature suggests that bundled interventions, such as 
the iLEAD protocol, are more likely to reduce the incidence of delirium and provide less 
robust evidence to support decreasing severity or duration of delirium.38 Alternatively, it 
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is important to consider that undetectable differences between the pre- and post-
implementation cohorts may exist. 
Interestingly, 30-day readmissions were not associated with SICU delirium either by 
study year or presence of delirium. This suggests that readmissions are related to other 
factors such as severity of illness, or complications of the disease process, and not 
delirium. Readmissions are both a clinical and financial problem. The Center for 
Medicare and Medicaid Services (CMS) began penalizing hospitals for 30-day 
readmissions starting in 2012.16 According to CMS, the national rate of 30-day all-cause 
readmissions observed for patients aged 65 and above in 2013 was 16.2%.39 The 
average cost of a readmission for this age group for any given cause was $13,800 (U.S. 
dollars) for those patients on Medicare.39 A portion of these costs are likely attributed to 
patients with delirium being re-admitted to the hospital. In other reports of the literature, 
little evidence is available describing the impact of days of delirium on hospital 
readmissions, a key driver of healthcare costs. The downward trend observed in 30-day 
hospital readmissions in this study is nonetheless favorable, and perhaps with a greater 
number of patients receiving iLEAD-informed care, these trends will reach significance.  
In both cohorts, rates of mechanical ventilation use among patients with delirium 
were comparable (65% vs 71%, p = 0.504) as were levels of sedation (RASS) (p = 
0.1198). Unexpectedly, patients in the post-implementation cohort spent a greater 
number of hours ventilated (66 hours, p = 0.032) than patients in the pre-implementation 
cohort (45 hours). To maintain compliance and comfort for patients on the ventilator, 
sedative medications, such as propofol and benzodiazepines, are typically used. These 
medications have potentially psychoactive effects on the central nervous system and 
have been associated with the development of deliruim.40-46 Greater exposure to these 
deliriogenic medications administered secondary to mechanical ventilation in the post-
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implementation cohort may have precluded noting appreciable effects of the iLEAD 
intervention. The results from the SCCM ICU Liberation Collaborative reported that 
implementation of the ABCDEF bundle was associated with a decreased rates of 
mechanical ventilation,26 thus once the iLEAD intervention achieves full strength, these 
results may continue to improve.  
Contemporary guidelines, and the iLEAD intervention, promote lighter sedation 
targets (RASS goals) to minimize the negative consequences of increased exposure to 
deliriogenic sedatives.22 In critical care patients, literature suggests that maintaining a 
deep level of sedation is associated with increased ICU length of stay, longer duration of 
mechanical ventilation, and acquired weakness due to immobility.47 A goal of the iLEAD 
intervention is to reduce the time a patient spends on the ventilator, incorporating the 
assistance of respiratory therapists, and spontaneous breathing trials. So, while all 
stakeholders may actively engage in the success of the iLEAD intervention, systems 
level factors related to respiratory therapist availability may explain some potential 
shortcomings of implementation. More research is needed to understand the 
interprofessional team dynamics to achieving successful outcome for these delirious 
patients. 
Admitting diagnoses were utilized as a proxy for severity of illness measures, as 
more traditional measures of illness severity (i.e., Acute Physiologic Assessment and 
Chronic Health Evaluation II (APACHE II) scores) were not exportable for analysis. 
Overall the two cohorts were comparable (p = 0.232) with respect to medical diagnosis 
on admission. Historically, patients who develop delirium are likely to be more critically ill 
than non-delirious patients.9,48 Therefore, it is possible that improved outcomes were not 
present due to unmeasured differences related to severity of illness between the two 
cohorts not captured by admitting diagnosis. Utilizing only the admitting diagnosis did not 
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allow for changes in medical status and comorbidities developed during the course of 
the SICU stay to be included in the analysis. These may present additional factors to 
evaluate in prospective investigations.  
Following iLEAD, the number of days where no CAM-ICU assessment was 
documented was drastically reduced. These results suggest that uptake of the 
intervention was high and support the analyses of the effect of iLEAD on delirium 
outcomes. Importantly, while the duration of delirious episode and number of delirious 
patients was similar per group, the number of patients with delirium-free/coma-free days 
(p = 0.0178) in 2018 increased significantly. Although this is primarily reflective of 
increased rates of screening, it allows the iLEAD team to understand delirium outcomes 
more fully among patients in the SICU. Literature proports delirium rates of 
approximately 50% in ICU populations,2 however the incidence in the pre and post 
iLEAD cohorts were 37% and 33% respectively, suggesting that overall rates of delirium 
in this population are well below the reported standard. With continued fidelity to the 
iLEAD intervention, we postulate that rates and duration will continue to decrease.  
As noted, implementation of the iLEAD protocol does not direct the nurse to utilize 
specific delirium interventions, rather allows them to choose from a menu of suggested 
interventions. Consequently, the lack of iLEAD effects may be related to nurses 
choosing fewer or less effective activities. At the time of data collection, the individual 
elements delivered were not captured in the EHR. Furthermore, the entire ABCDEF 
bundle had not yet been implemented. The interventions for early mobility (E) and family 
engagement (F) were not yet introduced during the study period. As these elements 
become implemented, patient outcomes may continually improve.  
The results the SCCM ICU Liberation Collaborative shows that implementation of the 
ABCDEF bundle can improve patient and health system-level outcomes. These results 
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should embolden HUP iLEAD team; with more time and enriched implementation, 
patient and systems-level outcomes in the SICU, and across all ICU’s implementing 
iLEAD across Penn Medicine, should continue to improve. 
Limitations 
Being an observational cohort study, patients were not randomized to receive the iLEAD 
intervention, thus subject to the threats of selection bias. The control group was 
historical, thus changes over time other than iLEAD implementation may have 
accounted for the findings. In addition, data collection was limited to that available in the 
EHR, and inconsistencies in the accuracy of the documentation is another limitation. Any 
conclusions drawn by this study regarding the contributions of the specific nursing’s 
interventions implemented will require prospective validation in future studies. Lastly, 
because this study was conducted within a single SICU, the outcomes may not be 
immediately exportable to other health systems. It is possible that the patient populations 
and baseline processes of care for delirium management may not be generalizable to 
other hospitals and health systems.  
Future Directions 
Literature that specifically addresses delirium management interventions for older adults 
admitted to the SICU is limited and primarily focuses on comparing pharmacologic 
approaches. This paper is one of the first to evaluate the patient-centered delirium 
outcomes following implementation of the nurse-led iLEAD intervention in the SICU. This 
analysis highlights the contributions of nurses to champion this effort by evaluating the 
assessment, management and treatment of patients with delirium by utilizing evidence-
based nurse-initiated interventions chosen from a validated list of options. The results of 
this study warrant prospective evaluation of the specific nurse-led iLEAD interventions 
employed in this study.  
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Conclusions 
Importantly, this work examines the management of delirium among older adult patients 
admitted to the SICU. To date, few studies have specifically examined this patient 
population. These results add to the growing body of literature on how to best care for an 
aging patient with delirium in the critical care setting. Overall, measurable patient 
outcomes were achievable in the early stages of the iLEAD intervention and may inform 
prospective systems-level organizational change.  
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Figures and Tables 
 
 
Figure 3.1 Conceptual Model of the Effects of iLEAD on ICU Delirium  
This conceptual model illustrates the relationships of risk factors outlined in the iLEAD 
protocol for delirium to the clinical outcomes of interest. When nurses implement the 
iLEAD intervention, it was hypothesized that patient outcomes (days of delirium, length 
of stay, readmissions and mortality) would improve. 
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Figure 3.2 Study Sample Consort Diagram 
Consort style diagram illustrating the inclusion and exclusion criteria used to evaluate 
the pre- and post-implementation cohorts. The 2017 sampling pool contained 101 
patients and the post-implementation 2018 sampling pool, 172 patients. Of the total 
sample, 37 and 56 patients screened positive for delirium in the 2017 and 2018 cohorts 
respectively and were included in the analysis.  
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Figure 3.3 Outcomes in Delirious and Non-Delirious Patients  
A) ICU Length of Stay 2017 B) ICU Length of Stay 2018. C) Hospital Length of Stay 
2017. D) Hospital Length of Stay 2018. E) 30-Day Readmission Rates. F) 30-Day 
Mortality Rates. 
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Figure 3.4 Pre-implementation (2017) and Post-implementation (2018) Outcomes 
of Patients with Delirium  
A) ICU Length of Stay. B) Hospital Length of Stay. C) 30-Day Readmissions and 
Mortality. 
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Table 3.1 Characteristics of Sample 
 2017 
N=101 
2018 
N=172 
 
Characteristics No Delirium  Delirium No Delirium  Delirium p-value# 
Number of Patients 64 37 (37%) 116 56 (33%) 0.511 
Age (years), median (range) 72 (65-92) 76 (65-91) 72 (65-92) 73 (65-88) 0.1278 
Sex (male), N (%) 40 (63%) 22 (59%) 75 (65%) 33 (59%) 0.959 
Weight (kg), median (range) 81 (47 – 129) 77 (50-120) 80 (45-133) 81 (44-172) 0.2457 
Race 
Asian 
Black or African American 
Hispanic 
Unknown  
White 
Other 
 
 
1 
9 
0 
1 
53 
0 
 
0 
4 
1 
5 
25 
2 
 
1 
9 
1 
15 
90 
0 
 
0 
7 
0 
6 
42 
1 
0.593 
Mechanical Ventilation % 
median hours (range) 
30% 
19 (2-168) 
65% 
45 (7-168) 
25% 
18 (1-168) 
71% 
66 (9 -168) 
0.504 
0.0320* 
RASS, median (range) 0 (-3 to 1) -1 (-3 to 1) 0 (-4 to 0) -1 (-2 to 0) 0.1198 
ICU Length of Stay, median (range) 3 (2,23) 7 (2, 44) 3 (2,23) 8 (2, 41) 0.7499 
Hospital Length of Stay, median 
(range) 
10.5 (3,139) 15 (3, 89) 9 (2,58) 17.5 (5,83) 0.1909 
Days of Delirium, mean ± sd -- 2.14 ± 1.4 -- 2.60 ± 1.7 0.1660 
Admitting Diagnosis  
(ICD-10-CM Codes)  
    0.232 
A00-B99 Infectious and parasitic 
diseases 
3 1 2 5 0.232 
C00-D49 Neoplasms 15 6 27 9 0.985 
E00-E89 Endocrine, nutritional and 
metabolic disease 
0 1 1 0 0.398 
H60-H95 Diseases of ear and 
mastoid process 
1 1 1 0 0.398 
I00-I99 Diseases of circulatory 
system 
4 3 16 11 0.128 
J00-J99 Diseases of respiratory 
system 
1 3 3 0 0.06 
K00-K95 Diseases of digestive 
system 
18 10 27 14 0.827 
L00-L99 Diseases of the skin and 
tissue 
2 0 0 0 -- 
M00-M99 Diseases of 
musculoskeletal system  
3 2 1 2 1.0 
N00-N99 Diseases of genitourinary 
system 
3 2 4 1 0.561 
Q00-Q99 Congenital 
malformations/abnormalities 
0 1 0 0 0.398 
R00-R99 Symptoms, signs & 
abnormal labs 
10 6 25 11 0.676 
S00-T88 Injury, poisoning & other 
external causes 
3 1 6 3 1.0 
Z00-Z99 Factors of health status  1 0 2 0 -- 
*indicates statistical significance. #p-values reflect comparison of patients with delirium between 2017 and 
2018.  
Abbreviations: (sd) standard deviation; (kg) kilograms; (ICD-10-CM) International Classification of Diseases, 
Tenth Revision, Clinical Modification. 
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Table 3.2 Daily CAM-ICU Assessments 
CAM-ICU Assessment Values 2017 2018 p-value 
Positive  0.78 ± 1.33 0.85 ± 1.56 0.7200 
No Test Performed  1.1 ± 1.4 0.45 ± 0.65 <0.001* 
Negative 2.45 ± 1.66 2.94 ± 1.69 0.0178* 
Unable to Assess (Coma)  0.29 ± 0.79 0.27 ± 0.77 0.8873 
*indicates statistical significance. 
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Chapter 4  
Evaluating the relationships among pain, opioid analgesic administration and the 
onset of delirium in older adults in the surgical intensive care unit 
Abstract  
Background. Analgesics are among the most commonly administered medications to 
patients in the surgical intensive care unit (SICU). Literature suggests that that both 
untreated pain and pain management with opioids are each independent precipitating 
factors for the development of delirium. However, there is limited and mixed evidence to 
support these assumptions, particularly among older adults in the SICU.  
Objectives. This cross-sectional secondary data analysis evaluates the relationships 
among pain severity, its management with opioids, and the onset of delirium in older 
adult patients admitted to the SICU.  
Methods. A convenience sample of consecutive patients aged 65 or greater admitted to 
the SICU over a 5-month period were examined (n = 172). Averaged 24-hour pain 
severity scores and opioid exposure were extracted from the electronic health record 
and examined with respect to the onset of next day delirium.  
Results. Opioids (chi-square [𝜒2], 12.60, P = .0004), but not pain (𝜒2, 3.61, P = .0573) 
were significant in predicting next-day delirium status. Controlling for pain severity, 
patients exposed to opioids exhibited odds of developing delirium were 2.5 times those 
of patients not exposed to opioids (95% Confidence Interval: 0.371-1.485).  
Conclusions. Examination of the relative roles of pain and opioid administration on the 
development of delirium experienced by this population provides evidence that opioids 
predict the onset of next-day delirium, which has implications for the use of these 
commonly administered mediations to older adults in the SICU setting. In an effort to 
prevent delirium, future research should focus on both pharmacological and non-
pharmacological opioid-sparing pain management approaches. 
 88 
Introduction 
Delirium is believed to occur in approximately 50% of all older hospitalized adults.1 It is 
defined as an acute change in cognition and attention not described by a pre-existing 
condition, established or evolving dementia.2 Delirium is a known risk factor for poor 
outcomes in patients admitted to the surgical intensive care unit (SICU),3-6 and is 
associated with longer hospital and intensive care unit (ICU) length of stay,7 persistent 
functional decline6,8-13 and mortality.3,14-17 Recent studies have shown that outcomes 
worsen as the duration of delirium increases.9,18,19 Further, delirium significantly 
increases health care costs, ranging from an additional $16,303 to $64,421 per patient.20  
 To date, no single pharmacological intervention has been shown to be effective in 
treating delirium.6 Multiple variables are believed to contribute to the development of 
delirium, including underlying health conditions, inflammatory processes, 
neurotransmitter disruptions, physiological stressors, and metabolic derangements,6,21-24 
however the pathophysiology of delirium remains poorly understood. While numerous 
risk factors for delirium have been identified,17,25-28 many are non-modifiable, such as 
admission to the ICU, duration of illness, and increased age.25-27 Current interventions 
for the prevention of delirium include ensuring pain, a modifiable risk factor, is 
adequately managed while minimizing the use of medications to treat pain, such as 
opioids.28,29  The finding that both pain, and its management, can contribute to the onset 
of delirium suggests that their relative roles in improving delirium outcomes warrant 
further investigation. 
 Pain is a potent and common stressor present in approximately 80% of critically ill 
patients admitted in the SICU,30 and is commonly identified as a precipitating factor for 
the development of delirium.31-34 However, there is surprisingly limited evidence to 
support a causal association between untreated pain and the development of delirium. 
Several older studies have examined how the presence of postoperative pain may 
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contribute to the occurrence of delirium, however the findings are mixed.31-34 Because 
the relationship between pain and delirium is not well-established, it is unclear that the 
pharmacological management of pain will prevent delirium in critically ill patients.  
 Medications are thought to account for 12% to 39% of all cases of delirium.25 
Specifically, results from systematic reviews show that opioid analgesics,28,29 
hypnotics,35-38 benzodiazepines,37,39 anticholinergic agents,25,32 antihistamines,25 and 
corticosteroids7,25 are each associated with the development of delirium. Opioids are the 
most common analgesics administered to patients following surgery, and morphine, 
fentanyl, and hydromorphone are those most frequently used.28,29 An association has 
been reported between opioid use and the development of delirium in patients admitted 
to an ICU26 and with the use of opioids in general across hospital settings.25 However, 
these studies have limited generalizability and are graded of low to moderate quality 
evidence.25,26,28  
 The aim of this investigation was to evaluate the relationships among acute 
postoperative pain severity, opioid analgesic administration and the onset of delirium 
among older adults in the SICU. As outlined in the conceptual framework (see Figure 
4.1), it is hypothesized that pain severity and opioid use are each positively correlated 
with the onset of delirium, and that opioid administration will decrease pain. These 
analyses enable comparison of the relative and combined roles of pain severity and 
opioid administration on delirium onset, providing direction for the management of these 
delirium risk factors. 
Methods 
Study Design  
Utilizing a longitudinal study design, data were collected from a single hospital SICU to 
examine the relationships among the onset of delirium, pain severity, and opioid 
analgesic administration in older adult patients aged 65 years or older. The observation 
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period was from March 15, 2018 to August 15, 2018. Daily average pain scores, daily 
worst pain scores, and daily opioid medication exposure were calculated from the time of 
ICU admission until discharge or up to 7 days and inspected to see how these predicted 
next-day delirium. Based on other reports in the literature, the sampling period was 
limited to 7 days as patients whose delirium emerges beyond 7 days may be suffering 
from an underlying medical abnormality or complications that are not representative of 
SICU delirium.26,40   
All data were extracted from the electronic health record (EHR). The University of 
Pennsylvania Institutional Review Board approved this exempt research project and 
granted a waiver of informed consent prior to its initiation. Study design and reporting 
criteria outlined in the STrenghtening the Reporting of OBservational studies in 
Epidemiology (STROBE) were followed.41  
Sample and Setting  
Study participants were selected from a 24-bed SICU at the Hospital of the University of 
Pennsylvania, which is a 795-bed, urban academic teaching hospital. Inclusion criteria 
were; age  65, English speaking, admitted to the SICU for >24 hours, and screened for 
delirium using the confusion assessment method for the intensive care unit (CAM-ICU) 
anytime between day 1 and day 7 during their admission to the SICU. Patients were 
excluded if they had an admitting diagnosis related to neurological or central nervous 
system injury; for patients readmitted to the SICU, only the index admission was 
evaluated.  
Measures  
Delirium. Delirium was identified using the highly reliable and well-validated CAM-ICU 
tool.42-44 Delirium was defined as one positive CAM-ICU screening in a 24-hour period 
calculated beginning at the time of ICU admission through ICU discharge or up to 7 
days. Delirium onset was defined as being free of delirium in the preceding 24-hours. 
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The CAM-ICU assessment was completed by trained nurses every 12 hours and 
recorded in the EHR.  
Pain. The nursing staff completed pain assessments every 4 hours beginning on 
admission to the SICU. Pain severity was measured using a self-reported 10-point 
numeric rating scale, where 0 indicates no pain and 10 indicates worst pain ever. Pain 
scores were extracted from the EHR and averaged for each 24-hour period during days 
1-7, providing an average daily pain score; in addition, the highest (worst) pain score 
recorded each day was extracted for analysis.  
Opioid Exposure. Daily opioid use was also extracted from the EHR for analysis. The 
opioids to which patients were exposed included; acetaminophen-codeine #3, fentanyl, 
hydromorphone, methadone, morphine, oxycodone, oxycodone-acetaminophen and 
tramadol. Routes of administration varied by medication and comprised oral, 
intravenous, epidural and patient controlled analgesia. Exposure was defined as any one 
instance of opioid administration (any type or route) during a 24-hour period.  
In addition, patient characteristics including age, sex, weight, race and admitting 
diagnosis were extracted from the EHR to describe the population of interest. Use of 
mechanical ventilation, Richmond Agitation-Sedation Scale (RASS) scores and sedative 
medications (benzodiazepines and propofol) were also examined as potential 
covariates.  
Statistical Methods 
To compare patients who developed delirium with those who did not, student’s t-tests for 
independent groups were used to assess continuous variables and chi-square (𝜒2) tests 
were used to assess categorical variables. P-values of 0.05 or less were considered to 
indicate statistical significance. Data were closely examined for any systematic patterns 
of missingness. Pain severity (24-hour average, daily worst) and opioid exposure were 
assessed as predictors of next-day delirium status using generalized estimating equation 
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models. The generalized estimating equations method was applied using the Genmod 
procedure in SAS, which is able to account for correlation within subjects’ repeated 
observations and allows for the assessment of time varying exposure covariates. Daily 
pain (24-hour average) and opioid exposure were assessed together as predictors of 
next-day delirium status in a multivariable general estimating equation model. Lastly, 
daily pain (24-hour average), opioid exposure, propofol exposure, mechanical ventilation 
and RASS were assessed together as predictors of next-day delirium status in a 
multivariable general estimating equation model. 
Results  
The final sample was comprised of 172 patients, 56 of whom experienced delirium 
during the SICU stay and 116 who did not. Demographically, the two cohorts were 
comparable (Table 4.1) and there were no differences in admitting diagnosis. As noted, 
both pain (24-hour average) and worst pain scores, averaged across Days 1 to 6, were 
slightly more severe for patients who did not develop delirium, although not to a 
statistically significant degree. Delirium was significantly associated with a higher 
number of days exposed to opioids (P = .0018) and propofol (P < .001) in comparison to 
patients who did not develop delirium, however not associated with a number of days 
exposed to benzodiazepines (P = .1253). In addition, patients who developed delirium 
received mechanical ventilation (P < .001) and for a greater number of hours (P < .001). 
When assessed using generalized estimating equation models, neither average pain 
score (𝜒2, 1.02, P = .3135) nor worst pain score (𝜒2, 0.93, P = .3353) were found to be 
significantly associated with next-day delirium onset (Table 4.2). There was however, a 
statistically significant association between opioid exposure and next-day delirium status 
(𝜒2, 11.53, P = .0007). Specifically, the odds of next-day delirium for a patient treated 
with opioids were 2.2 times those of a patient not treated with opioids (95% Confidence 
Interval [CI]: 1.300-3.638). In that propofol was found to be significantly associated with 
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delirium in the initial descriptive analysis, it was assessed as a predictor of next-day 
delirium in a generalized estimating equation model. Propofol exhibited a statistically 
significant association with next-day delirium status (𝜒2, 10.29, P = .0013), and the odds 
of next-day delirium for a patient receiving propofol were 2.7 times those of patients who 
were not exposed to propofol (CI: 1.457-4.916).  
Daily pain severity (average) and opioid exposure were assessed together as 
predictors of next-day delirium status in a multivariable general estimating equation 
model (Table 4.3). Again, opioids (𝜒2, 12.60, P = .0004), but not pain (𝜒2, 3.61, P = 
.0573) were statistically significant in predicting next-day delirium status. When 
controlling for pain severity, patients exposed to opioids exhibited odds of next-day 
delirium that were 2.5 times those of patients not exposed to opioids (CI: 0.371-1.485). 
Because propofol exposure was a strong predictor of next day delirium in the 
descriptive analysis, it plus the indications of propofol administration (mechanical 
ventilation, RASS score), were assessed with daily pain severity (average) and opioid 
exposure as predictors of next-day delirium status in a multivariable general estimating 
equation model. Opioids (𝜒2, 5.02, P = .0251) remained statistically significant in 
predicting next-day delirium status; however pain (𝜒2, 0.99, P = .3189), propofol 
exposure (𝜒2, 2.75, P = .0974), use of mechanical ventilation (𝜒2, 1.86, P = .1723) and 
RASS (𝜒2, 1.82, P = .1771) were not statistically significant in predicting next-day 
delirium status (Table 4.4). In the multivariable model, the odds of next-day delirium for 
a patient exposed to opioids were 1.9 (CI: 1.0042 – 3.4925) and for patients exposed to 
propofol 1.9 (CI: 0.9568 – 3.7922) times those of a patient not exposed to either drug 
respectively.  
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Discussion  
Both untreated pain and opioid analgesics have been implicated in the development of 
delirium in older adults in the intensive care unit setting.31,32,34,45 Our analyses evaluated 
the relative role of these risk factors in predicting delirium onset in a well-characterized 
sample of older adult patients in the SICU. The results indicate that medications play a 
greater role in delirium development than pain and suggest that medication 
administration may be a modifiable risk factor to mitigate its occurrence. 
Pain regularly occurs in adult ICU patients and can impede patients from actively 
participating in their care (e.g., early mobilization, participation in spontaneous breathing 
trials, weaning from mechanical ventilation).45 The stress response produced by acute 
pain can lead to negative, both short- and long-term consequences for adults in the ICU. 
Specifically, acute pain is a risk factor for developing chronic, persistent, often 
neuropathic pain.46 Untreated pain is an oft-cited precipitating factor of delirium; in fact, 
The Society for Critical Care Medicine identifies pain as a modifiable risk factor for the 
development of delirium.45 Nevertheless, empirical evidence supporting its relationship 
on the development of delirium is surprisingly limited32,34,47 and few studies have 
examined how the presence of pain contributes to the occurrence of delirium in the SICU 
population specifically.34  
A study of 361 patients undergoing major elective noncardiac surgery evaluated pain 
at rest, pain with movement, and maximum pain. The authors found that in when 
stratified by surgical procedure, patients with higher pain scores at rest were at 
increased risk of developing delirium of the three postoperative days studied (risk ratio 
1.2, P = 0.015).32 Similarly, Vaurio and colleagues studied 333 older adults scheduled for 
non-cardiac surgery concluded that severe pain (OR, 3.7; 95% CI 1.5 to 9.0) was 
independently associated with the development of delirium.34 Newer evidence has not 
sufficiently drawn definitive conclusions between the relationship of pain and delirium, 
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which may be related to the practice of aggressively treating pain in the acute care 
setting.  
Our results demonstrated that average and worst pain score were not predictive of 
next-day delirium status. As noted, weekly averaged pain scores were in the low to 
moderate range. Although insignificant, patients with delirium had lower pain severity 
ratings than those patients without delirium, suggesting that opioid provision, although 
deliriogenic, was also an effective analgesic. The results of this investigation provide 
additional support that while unrelieved pain may lead to its own detrimental 
consequences, it may not be predictive of the development of delirium and suggest that 
pain management with opioids may be responsible for confounding this relationship.  
Consistent with the results of a systematic review,25 opioids were a strong predictor 
of delirium onset, more than doubling the odds of delirium developing the day following 
opioid administration (APPENDIX C). After evaluating the literature, two studies have 
indicated protective effects of opioids reporting reduced rates of delirium,48,49 four studies 
show no association between opioids and delirium status,50-53 and seven studies 
attributed opioid use to the development of delirium.25,26,47,54-57 Our results will add to this 
growing body of literature implicating opioid use as a risk factor for delirium.  
Opioids have known psychoactive and depressant effects on cortical function, 
resulting in diminished cognitive performance, which has been implicated in the decline 
in cognitive function hallmark of delirium.58 Opioid-induced delirium is thought to be the 
result of underactivity of the cholinergic system.1,59 In the central nervous system, 
cholinergic projections from the basal forebrain to the thalamus and cortex are critical in 
supporting key cognitive functions, such as maintaining alertness, sustaining attention, 
and learning and memory.60-62 Opioids appear to impair cognitive processing, leading to 
the development of delirium, due to obstruction of this vital cholinergic transmission.63,64 
Inhibition of acetylcholine from morphine has also been implicated in decreasing rapid 
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eye movement (REM) sleep and disrupt sleep architecture.65 These perturbations in 
sleep architecture may then, in turn, affect arousal and lead to impaired attention, which 
are early indicators of the development of delirium.66  
Disruption of the cholinergic system has also been associated with the memory 
deficits in Alzheimer's disease. A substantial proportion of patients who survive delirium 
are likely to experience long-term cognitive impairment similar to mild Alzheimer’s 
disease6,8-13 for up to one year post-discharge.19 A recent study placed the odds of 
requiring of institutional care post-hospitalization at rates 2.4 times higher in patients 
who suffer from delirium than those who did not,17 suggesting that opioid exposure in the 
SICU may not only be associated with delirium onset, but also post-delirium memory 
deficits. The results of this study add to the growing body of literature reporting an 
association between opioid use and the development of delirium in patients admitted to 
an ICU25,26,67 and with the use of opioids in general across hospital settings.25  
Historically, benzodiazepines (i.e., midazolam and lorazepam) and propofol have 
routinely been used to provide sedation in the ICU. Older guidelines recommended 
midazolam for short-term sedation, lorazepam for long-term sedation, and propofol for 
patients requiring occasional awakenings.68 As an emphasis on delirium-related patient 
centered outcomes have become more prevalent, trials began implicating 
benzodiazepines as a likely culprit for delirium.37,39,69 While this association was not 
noted in our sample, exposure to benzodiazepine was limited and under-powered to 
capture this effect (post-hoc power analysis, 33% power to detect statistical significance 
at the alpha = 0.05 level). Low rates of exposure to benzodiazepines in this sample likely 
reflect benzodiazepine-sparing practices in the SICU to avoid deliriogenic effects.  
The 2018 Society of Critical Care Medicine guidelines now recommend propofol, 
over benzodiazepines, as first-line sedation for most patients in the ICU.45,70 
Interestingly, while significantly associated with delirium alone, after controlling for 
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mechanical ventilation and RASS as covariates, the deliriogenic effect of propofol on 
next day delirium was weakened. Propofol is routinely used due to its quick onset, short 
duration of action, and relatively low cost.38,63 While exposure to propofol has the 
potential for sedative and psychoactive effects such as impaired memory and delayed 
motor performance,71 the mechanism by which it causes delirium is unclear. A review 
article by Brown and colleagues cite evidence from in vitro studies suggesting that 
propofol may interact with acetylcholine receptors.72 Similar to opioids, this cholinergic 
deficit may also be responsible for propofol delirium-inducing side effects.  
Our finding that propofol exposure was associated with next-day delirium status, 
support and extend those of other studies that have examined the association between 
propofol and delirium. The association between delirium and propofol use has been 
evaluated in 15 studies; three descriptive and 12 comparison studies (APPENDIX D). 
Two out of three descriptive studies73-75 correlated propofol administration with increased 
rates of delirium. In a study of 149 patients admitted to the ICU, 69 developed delirium 
(46.3%) and propofol was administered to 23 patients (33.3%) of these patients, 
compared to just 6 patients (7.5%) without delirium (P < .001).74 In a sample of 115 
patients, Bryczkowski and colleagues, reported higher average cumulative doses of 
propofol in patients with delirium (6 mg/kg/d vs. 1 mg/kg/d; P < .001).75 Finally, a study of 
451 patients undergoing spinal surgery found that 42 patients (9.3%) developed 
delirium, and there was no appreciable difference in the use of propofol between those 
who developed delirium and those who did not.73 
As the hallmark of routine sedation, propofol is often used as an active comparator in 
clinical trials evaluating alternative medications for the reduction of delirium outcomes in 
the ICU. When used as a comparator in clinical trials, some, but not all studies confirm 
that propofol results in worse delirium-related outcomes. Comparators included one 
study of opioids, one study of benzodiazepines and ten studies utilizing 
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dexmedetomidine. A retrospective study of 100 patients compared fentanyl sedation (n = 
50) versus traditional sedation with propofol (n = 50) found no difference in the 
development of delirium between groups (P = .80).53 In a sample of 140 patients 
admitted to the ICU receiving propofol or benzodiazepines for sedation, higher daytime 
administration of propofol was marginally (P = .60) associated with next-day delirium 
onset.76  Of the ten studies evaluating propofol versus dexmedetomidine for the 
reduction of delirium, no study reported propofol superior to dexmedetomidine for the 
reduction or prevention of delirium. Four studies reported superiority with 
dexmedetomidine,35,36,77,78 and six studies showed no difference in the incidence of 
delirium between groups.38,79-83 Ultimately, more studies are needed to understand the 
role of propofol as a precipitating factor in the development of delirium. The results of 
this investigation add to the growing body of literature, suggesting that even a single 
exposure to propofol may increase the likelihood for developing delirium in the SICU.  
Sedatives, like propofol and benzodiazepines, are regularly used in the ICU to 
mitigate the agitation associated with mechanical ventilation. Recent literature indicates 
that both maintaining a deep level of sedation (measured by RASS) and longer duration 
of mechanical ventilation are associated with the development of delirium, increased ICU 
length of stay, and acquired weakness due to immobility.84 Because propofol exposure 
was significant in the exploratory analysis, RASS and use of mechanical ventilation were 
added as covariates to the final model to test their association with the onset of next day 
delirium status. Notably, patients with delirium spent approximately 66 hours (median) 
on mechanical ventilation compared to just 18 hours in patients without delirium. In the 
multivariable analysis, mechanical ventilation did not increase the odds of next day 
delirium, suggesting that the medication administered to manage mechanical ventilation 
(propofol), not the ventilation itself, was associated with the development of next-day 
delirium. Importantly, RASS between the two groups was similar with average scores in 
 99 
range of light sedation (RASS = 0, -1), and was not significantly associated with the 
development of next day delirium. These analyses enabled comparison of the relative 
and combined roles of pain severity, opioid and propofol exposure, mechanical 
ventilation and RASS on the onset of delirium, providing direction for management of 
these modifiable delirium risk factors.  
The role of opioids and propofol in the development of delirium may be due to 
interruptions of the natural sleep-wake cycles.6,66,70,85 Recent evidence supports the 
promotion of sleep, aiming to provide at least 4 hours of sleep per night, for the reduction 
of delirium.86 One study has reported that delirium was associated with greater circadian 
sleep-cycle disruption and increased daytime sleep.85 The Society of Critical Care 
Medicine updated their Pain, Agitation and Delirium (PAD) guidelines were recently 
updated to now include Immobility (rehabilitation/mobilization), and Sleep (disruption) 
(PADIS). Importantly, only two of the 37 recommendations are graded as strong; most 
are conditional (the evidence is conflicting, low quality, insufficient). The specific 
recommendations related to sleep are conditional, with low to very low evidence. The 
committee hopes that by adding sleep to the guidelines it will encourage the completion 
of pragmatic, patient-centered research to answer these important critical care demands. 
Limitations  
There are several important limitations of this study. Due to limitations in the dataset, 
only dichotomous medication exposures (opioid, propofol, benzodiazepines) were 
evaluated. Therefore, potential effects of dose or route of administration were unable to 
be derived. In addition, no medication exposure or pain score information was available 
prior to arrival in the ICU, so their predictive role for day 1 delirium status was unable to 
be evaluated. Also, as noted, aggressive pain management and low rates of 
benzodiazepine use in the SICU may have precluded a true assessment of the effects of 
each on delirium onset. 
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The approach and findings are limited to the data collected during the defined study 
period. Due to lack of randomization to medication exposure or pain levels, selection 
bias is a potential threat to the internal validity of the study, and it is possible the 
observed changes may not be attributed to the medication exposure. It is also possible 
that the patient populations and baseline processes of care for delirium management at 
HUP may not be generalizable to other hospitals and health systems.  
Future Directions 
Literature that specifically addresses the relationships among delirium, pain severity and 
analgesia and sedation management for older adults admitted to the SICU is growing. In 
that opioid exposure was the strongest predictor of delirium onset in this study, opioid-
sparing approaches may be the best intervention to prevent its development. Pragmatic 
clinical trials are needed to prospectively evaluate if reduction in opioid administration, 
and pain control with non-opioid pharmacologic strategies are successful in reducing the 
onset of delirium. As health care systems respond to the opioid epidemic, opioid-sparing 
strategies for pain management in acute care settings are encouraged.87 Therefore, 
other types of analgesics and non-pharmacologic pain management approaches may be 
considered as covariates in future analyses.  
Contemporary guidelines, such as ICU Liberation, encourage lighter sedation targets 
to minimize the negative consequences of deep sedation,45,70 and consequently, may 
reduce exposure to propofol. A number of alternative pharmacological strategies to both 
prevent and treat delirium have been, and continue to be, highly tested including, 
antipsychotic medications,54 acetylcholinesterase inhibitors,88 melatonin,89 and 
gabapentin.88 Studies purport that dexmedetomidine may reduce or prevent 
delirium,6,22,24,66,77,90-93 and recent studies of intravenous acetaminophen are receiving 
praise as a possible alternative to opioids due to the analgesic and inflammatory 
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properties of the drug.83 Thus far, no single strategy has amassed enough evidence to 
support its role in delirium prevention or treatment.  
Conclusions 
This study is among the few to characterize the relative relationships among pain, opioid 
analgesia and sedation with propofol in the onset of delirium in older adults admitted to 
the SICU. Pain was not found to be a contributor to next-day delirium status however, 
both opioid and propofol exposure were strong predictors of delirium onset in this 
sample. Future research should focus on medication-sparing approaches to manage 
pain and achieve sedation as a means to prevent delirium. 
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Figures and Tables 
 
Figure 4.1 Conceptual Model of the Effects of Pain and Opioid Analgesia on 
Delirium 
This conceptual framework postulates that pain severity and opioid use are each 
positively correlated with the onset of delirium, and that opioid administration will 
decrease pain.  
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Table 4.1 Characteristics of Sample 
Characteristics No Delirium  Delirium p-value 
Number of Patients 116 56  0.464 
Age (years), median (range) 72 (65, 92) 73 (65, 88) 0.6249 
Sex (male), n (%) 75 (65%) 33 (59%) 0.467 
Weight (kg), median (range) 80 (45, 133) 81 (44, 172) 0.9980 
Race 
Asian 
Black or African American 
Hispanic 
Unknown  
White 
Other 
 
 
1 
9 
1 
15 
90 
0 
 
0 
7 
0 
6 
42 
1 
0.530 
Medication Exposures, mean days ± sd 
Opioids 
Propofol  
Benzodiazepines 
 
 
1.2 ± 1.7 
0.2 ± 0.7 
0.2 ± 0.7 
 
2.0 ± 2.2 
1.1 ± 1.6 
0.4 ± 1.0 
 
<0.0018* 
<0.001* 
0.1253 
 
Pain Scores (0-10) Days 1 to 6, median (range) 
Average 
Worst 
 
3.7 (0, 8.7) 
4.2 (0, 9.8) 
 
2.7 (0. 8.2) 
3.5 (0, 9.3) 
 
0.2453 
0.1936 
Mechanical Ventilation % 
median hours (range) 
29 (25%) 
18 (1-168) 
40 (71%) 
66 (9 -168) 
<0.001* 
<0.001* 
RASS median (range) 0 (-4 to 0) -1 (-2 to 0) 0.39 
Admitting Diagnosis (ICD-10-CM Codes)    0.365 
A00-B99 Infectious and parasitic diseases 2 5 0.26 
C00-D49 Neoplasms 27 9 0.265 
E00-E89 Endocrine, nutritional and metabolic 
disease 
1 0 1.0 
H60-H95 Diseases of ear and mastoid process 1 0 1.0 
I00-I99 Diseases of circulatory system 16 11 0.335 
J00-J99 Diseases of respiratory system 3 0 0.552 
K00-K95 Diseases of digestive system 27 14 0.827 
M00-M99 Diseases of musculoskeletal system  1 2 0.250 
N00-N99 Diseases of genitourinary system 4 1 1.0 
R00-R99 Symptoms, signs & abnormal labs 25 11 0.752 
S00-T88 Injury, poisoning & other external causes 6 3 0.969 
Z00-Z99 Factors of health status & contact health 
services 
2 0 1.0 
*indicates statistical significance.  
Abbreviations: (kg) kilogram; (sd) standard deviation; (ICD-10-CM) International Classification of Diseases, Tenth 
Revision, Clinical Modification. 
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Table 4.2 Odds of Pain and Medication Predicting Next-Day Delirium 
 chi-square p-value Odds Ratio 95% Confidence Interval 
Pain Score - Average 1.02 0.3135 0.95 0.86 - 1.05 
Pain Score - Worst 0.92 0.3353 0.96 0.88 - 1.05 
Opioid Exposure 11.53 0.0007* 2.2 1.30 - 3.64 
Propofol Exposure 10.29 0.0013* 2.7 1.5 - 4.92 
*indicates statistical significance 
 
 
Table 4.3 Predictors of Next-Day Delirium 
 chi-square p-value Odds Ratio 95% Confidence Interval 
Pain Score - Average 3.61 0.0573 0.90 0.81 – 1.00 
Opioid Exposure 12.60 0.0004* 2.50 1.45 - 4.42 
*indicates statistical significance 
 
Table 4.4 Multivariate Predictors of Next-Day Delirium 
 chi-square p-value Odds Ratio 95% Confidence Interval 
Pain Score - Average 0.99 0.3189 0.95 0.84 – 1.06 
Opioid Exposure 5.02 0.0251* 1.9 1.0042 – 3.49 
Propofol Exposure 2.75 0.0974 1.9 0.96 – 3.79 
Mechanical Ventilation 1.86 0.1723 0.43 0.14 - 1.31 
RASS 1.82 0.1771 0.58 0.27 - 1.26 
*indicates statistical significance 
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Chapter 5  
Discussion  
Delirium affects more than 2.6 million older adults admitted to the intensive care unit 
(ICU) each year and can be a life-threatening.1 Nurses are uniquely prepared to drive 
solutions to address this clinically significant problem by recognizing risk factors and 
initiating evidence-based nursing interventions. The Hospital of the University of 
Pennsylvania created the ICU Liberation Executing the ABCDEF Bundle Daily (iLEAD) 
protocol to implement the ABCDEF bundle and reduce the consequences of delirium in 
the ICU. The overall objectives of this research were to describe the effectiveness of 
the iLEAD intervention to reduce the burden of delirium and its associated adverse 
outcomes, and to examine the relative roles of two modifiable risk factors associated 
with delirium (pain, opioid administration).  
Chapter 2 of this proposal served as the groundwork for the research aims and 
hypotheses by providing an increased understanding of the most current treatment 
strategies, delirium research methods, and the issues associated with identifying and 
managing delirium. Appreciative of deficits in delirium identification and management, 
Chapter 3 evaluated the efficacy of a new nurse-led preemptive identification, treatment 
and management strategy (iLEAD) to improve delirium-related patient and clinical  
outcomes (days of delirium, length of stay, readmissions and mortality). Lastly, Chapter 
4 continued investigation into the link between pain, opioid pain management, and the 
onset of delirium. Overall, this dissertation research has important implications in moving 
forward nurse-driven approaches to the clinical care of older adults in critical care 
environments at risk for experiencing delirium. 
  This dissertation research contributes to the existing knowledge that delirium is 
detrimental to the health of older adults. Importantly, the work brings attention to 
proposed risk factors for delirium in surgical intensive care patients, pain, and its 
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treatment with opioids. Continued investigation into the relative roles of pain and pain 
management on the onset of delirium will be invaluable for future delirium research and 
is vital to improve patient outcomes in older adults.  
Major Findings from Chapter 2 
There is inadequate, conclusive, evidence supporting pharmacologic interventions for 
the treatment or prevention of delirium. This integrative review of 16 peer-reviewed 
publications examined the efficacy of the novel alpha-2 agonist, dexmedetomidine in 
lowering the incidence of delirium compared to other analgesic and sedation strategies. 
The results of this analysis suggest that dexmedetomidine administration does not 
reduce the incidence and/or duration of delirium uniformly across all patient populations 
studied. However, there was good evidence to support postoperative administration of 
dexmedetomidine reduces delirium in patients, particularly following cardiac surgical 
procedures, supporting the results of recent meta-analysis.2 Further research is needed 
to determine the benefits of dexmedetomidine in patients on mechanical ventilation and 
optimal timing and duration of administration.  
As with much of the research in this field, the focus was on evaluating pharmacologic 
strategies to treat delirium. In future work, non-pharmacologic delirium interventions, 
pain management, and quality of sleep need to be included in these validation studies. 
Importantly missing from this literature is the effect of independent nursing interventions 
on delirium outcomes. Each of these dimensions (pain management, sleep, and 
medication administration) are areas in which nurses are important stakeholders and 
should help drive this research forward. As the population continues to age and the 
incidence of comorbid illnesses grows, addressing the prevention and reduction of 
delirium is a timely and imperative objective. The results of this integrative review were 
vital for elucidating the insufficiencies in delirium identification and management 
addressed in Chapters 3 and 4. 
 114 
Major Findings from Chapter 3 
The iLEAD is a nurse-driven protocol aimed at reducing the severity of delirium in the 
intensive care unit via the implementation of independent nursing interventions. When 
nurses routinely assess and manage modifiable risk factors for delirium, it was 
hypothesized that the number of days of delirium would decrease and patient outcomes 
would improve. Specifically, this retrospective study evaluated the impact of the iLEAD 
intervention on the number of days with delirium, length of stay in the SICU, overall 
hospital length of stay, 30-day readmission rates and 30-day mortality experienced by 
older adults in the SICU with delirium.  
Following iLEAD, implementation rates of delirium screening more than doubled, 
reflecting that nursing staff were highly motivated to address this critical issue facing 
patients in the SICU. Consistent with previous reports, patients with delirium in this study 
had increased SICU and overall hospital length of stay, and higher 30-day mortality rates 
when compared to patients without delirium. Other than a trend for improvements in 
rates of 30-day readmissions, no statistically significant improvements in delirium 
outcomes were noted for the patients who received iLEAD delirium-informed care. 
However, benefits associated with the iLEAD intervention may not have been detected 
because previously undiagnosed incidents of delirium (pre-implementation) were now 
identified (post-implementation), increasing measurement of the overall negative 
outcomes. Despite the lack of statistical significance, the clinical implications remain 
significant. Reducing delirium-related consequences even by one day may have 
substantial significance for patients, both in terms of health outcomes and healthcare 
related costs. As the iLEAD intervention continues to be implemented, patient-centered 
outcomes may show additional improvement. Delirium continues to be a noteworthy 
threat to the health of older adults, and dedicated nurse stakeholders are essential in 
advancing research. 
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Major Findings from Chapter 4 
This cross-sectional secondary analysis study of older adult patients admitted to the 
SICU evaluated the relationships among pain severity, its management with opioids, and 
the onset of delirium. Examination of the relative roles of pain and opioid administration 
on the development of delirium experienced by this population are important contributors 
to evidence-based guidelines on pain management. Developing approaches that 
maximize pain relief while minimizing the negative outcomes related to delirium are 
essential. The results of this investigation show that opioid exposure was the greatest 
predictor of next-day delirium status, followed by propofol administration. Interestingly, 
neither daily average nor worst pain score were associated with next day delirium. 
As the most commonly administered medications to patients in the SICU, the roles of 
opioids and propofol in delirium onset requires further explication. Medications are 
thought to account for 12% to 39% of all cases of delirium.3 The results of this 
investigation provide additional support that while untreated pain may have detrimental 
consequences, it may not be predictive of the development of delirium. In the literature, 
the language surrounding pain and delirium suggests causation, however this may be 
inappropriate given the potential for the confounding of observational data in a syndrome 
with intersecting, poorly understood, and underlying pathologic mechanisms. This 
observational research study cannot demonstrate causality but offers additional 
description of the relationship between pain and delirium. Too many studies have 
posited the causal link between pain and delirium with too few studies actually 
supporting this relationship, and more rigorous evidence is profoundly lacking. 
Limitations 
It is important to recognize several limitations of this research. First, patients were not 
randomized to receive the iLEAD intervention. Therefore, selection bias is a possible 
threat to the internal validity of this study. Second, data collection was limited to the 
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electronic health record, and inconsistencies in the accuracy and documentation of the 
assessments performed is another potential limitation to interpretation. Any conclusions 
drawn by this study regarding the contributions of the specific nursing’s interventions 
implemented will require prospective validation in future studies.  
Lastly, due to the retrospective observational nature of these analyses, the ability to 
demonstrate causation is not possible. It does, however, afford an important opportunity 
to examine the association between routine screening and patient outcomes for delirium, 
along with the associations among pain, its management with opioids, sedation and 
delirium onset. These investigations represent the first studies to evaluate the iLEAD 
intervention, originally designed as a health systems science initiative. Therefore, this 
observational approach took advantage of the natural experimental nature of this 
protocol implementation in effort to provide health systems and organization-level 
feedback. As such, the outcomes may not be immediately exportable to other health 
systems. It is also possible that the patient populations and baseline processes of care 
for delirium management may not be generalizable to other hospitals and health 
systems. 
Implications 
Importantly, this investigation is the first evaluation to determine the impact of iLEAD 
bundled independent nursing interventions to treat the significant and costly problem of 
ICU delirium. Nurses’ clinical expertise and front-line responsibilities make them uniquely 
qualified to champion these efforts. The implications of this health systems science 
dissertation research demonstrate that nurse-led interventions for the reduction and 
prevention of delirium are feasible, and potentially, as time goes on, may be effective.  
 Close examination of the literature reveals that there is little empirical evidence to 
support the causal relationship between pain and the development of delirium. Pain 
severity was not predictive of delirium in this sample, however exposure to the class of 
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analgesic most commonly used to treat pain, the opioids, made the patient twice as 
likely to result in next-day delirium. This suggests that opioids, administered to counter 
pain, contribute to delirium development. The role of pain management with opioids in 
the development of delirium requires explication. This study is among the few to 
characterize the relative roles of pain and opioid administration on the onset of delirium 
in the surgical ICU population.  
Sedatives, like propofol and benzodiazepines, are regularly used in the ICU to 
mitigate the agitation associated with mechanical ventilation. While significantly 
associated with delirium alone, after controlling for mechanical ventilation and RASS as 
covariates, the deliriogenic effect of propofol on next day delirium was weakened. The 
use of mechanical ventilation varied greatly in the sample however, it did not increase 
the odds of next day delirium, suggesting that propofol administration, not the ventilation 
itself, was associated with the development of next-day delirium. These analyses 
enabled comparison of the relative and combined roles of pain severity, opioid and 
propofol exposure, mechanical ventilation and RASS on the onset of delirium, providing 
direction for management of these modifiable delirium risk factors.  
In summary, this research evaluated the effectiveness of the nurse-led iLEAD 
intervention to reduce the burden of delirium and its associated adverse outcomes. 
Further, it examined two modifiable risk factors associated with delirium (pain, opioid 
administration). Overall, this dissertation research has important implications in moving 
forward nurse-driven approaches to the clinical care of aging adults in critical care 
environments at risk for experiencing delirium.  
Future Directions 
The older adult population is at the greatest risk for developing ICU delirium, and, at 
present, there is no consensus on best strategies for its prevention or management. 
Most studies focus on pharmacologic strategies to reduce delirium, while far fewer have 
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included reports of non-pharmacological interventions (see Table 1.1) as part of their 
reduction strategies. The lack of this information makes it difficult to assess if these non-
pharmacologic strategies, incorporated in many ICUs, play a role in the reduction of 
delirium. Despite limited evidence, use of such supportive measures has nevertheless 
become standard practice on the basis on clinical experience and lack of adverse 
effects. Formally evaluating these non-pharmacologic strategies represents a rich 
opportunity for future research. 
In addition, there is significant knowledge to be gained from the Hospital Elder Life 
Program (HELP), designed by Dr. Sharon Inouye and colleagues. HELP is an evidence-
based, patient-care program to maximize independence for older adults post-
hospitalization.4 The HELP program focuses on consistently reorienting patients to their 
surroundings, ensuing nutritional goals are meet, prioritizing sleep-promoting 
interventions while encouraging mobility during hospitalization. Rates of delirium in 
elderly patients have been significantly improved following the HELP program. With 
more than 200 HELP sites, the program has been successful in returning older adults to 
their homes (or prior living situations) with preserved or improved cognitive and physical 
function. A community hospital employing the HELP program evaluated 595 patients 70 
years of age or older admitted to a general medicine floor, and reported a 40% reduction 
in delirium incidence resulting in a cost savings of $841,000 over 9 months.5 The HELP 
program relies on the support of highly trained and supervised volunteers to enable one-
to-one support and delivery of personalized interventions to achieve optimal outcomes. 
While many large-scale health systems may find it difficult to achieve this level of 
personalized care, the associated cost savings may provide financial incentive to 
incorporate these strategies.  
The short-term consequences of pharmacologic pain management strategies may 
contribute to the development of delirium. Pragmatic clinical trials are needed to 
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prospectively evaluate if reduction in opioid administration, and pain control with non-
opioid pharmacologic strategies, are successful in reducing the onset of delirium. A 
number of alternative pharmacological strategies to both prevent and treat delirium have 
been, and continue to be, highly tested. Thus far, no single strategy has amassed 
enough evidence to support its role in delirium prevention or treatment. While 
dexmedetomidine has shown promise, additional studies are needed.  
A possible explication for the role of opioids and propofol in the development of 
delirium may be due to interruptions of the natural sleep-wake cycles. Recent evidence 
supports the promotion of sleep, aiming to provide at least 4 hours of sleep per night, for 
the reduction of delirium.6 Dexmedetomidine is an attractive choice for delirium therapy 
or prevention, as it is believed to mimic natural sleep architecture and reduce pain. If 
sleep is a potential curative or preventative measure for reducing the incidence of 
delirium, nighttime administration of dexmedetomidine may be advantageous in aligning 
patients with their natural circadian rhythms to facilitate more restful and restorative 
sleep. Validation studies are needed to evaluate day-time versus nighttime drug 
administration. In addition, metrics of quality of sleep should be included in other 
prospective evaluations of delirium, including those using opioids and propofol as active 
comparators.  
Conclusions 
In conclusion, this dissertation research contributes to the current understanding of the 
consequences of delirium among older adults in the surgical intensive care unit. This 
work described the effectiveness of the nurse-led iLEAD intervention to reduce the 
burden of delirium and examined two modifiable risk factors associated with delirium 
(pain, opioid administration). This dissertation research expands knowledge of delirium-
related patient and clinical outcomes (days of delirium, SICU length of stay, hospital 
length of stay, 30-day readmissions and 30-day mortality) and facilitates continued 
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investigation into the link between pain, opioid analgesics and the onset of delirium. 
Overall, this dissertation research has important implications in moving forward nurse-
driven approaches to the clinical care of aging adults in critical care environments at risk 
for experiencing delirium.   
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APPENDIX A  
iLEAD Protocol 
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APPENDIX B  
Study Variables and Operational Definitions 
Type  Variable Definition Measured by Units/Range/Frequency Data Type  
Independent  iLEAD 
(Specific Aim 2) 
A nurse-led intervention assessing and 
managing risk factors for delirium. 
Time period Pre vs. Post Dichotomous 
Independent Pain scores 
(Specific Aim 3)  
A measure a patient's pain intensity. Numeric Pain 
Scale  
0 - 10 
Every 4 hours 
Numeric continuous, ratio 
Independent Opioid exposure 
(Specific Aim 3) 
Opioids administered to treat pain. Exposure Yes/No Dichotomous 
Dependent  Days of Delirium  A positive CAM-ICU score in 24-hour period 
equals one day of delirium. 
Days Positive/Negative  
Every 12 hours  
Numeric continuous, ratio 
Dependent Length of stay (SICU)  Number of days of SICU stay  Days Days (24 hrs) Ratio 
Dependent Length of stay (Hospital) Total number of days hospitalized  Days Days (24 hrs) Ratio 
Dependent 30-day Readmission  
 
A subsequent hospital admission within 30 days 
following discharge.  
EHR Incidence of readmission Dichotomous 
Dependent 30-day Mortality  Death (all-cause) occurring 30 days following 
hospital admission.  
EHR Incidence of death Dichotomous 
Covariate  Age The number of years a person has lived.  EHR Years Continuous  
Covariate Sex The physiological state of being male or female.  EHR Male/Female Nominal, categorical  
Covariate Admitting Diagnosis  The condition identified by the physician at the 
time of admission. 
EHR Type  Nominal, categorical  
Covariate Mechanical Ventilation  A device that helps patients breathe  EHR Use and duration (hrs) Dichotomous/ Continuous  
Covariate Richmond Agitation-Sedation 
Scale (RASS) 
A measure of a patient’s level of sedation. EHR -5 to +4 
Every 4 hours 
Continuous, ratio 
Covariate Propofol Exposure Propofol administered for sedation  Exposure Yes/No Dichotomous 
Covariate Benzodiazepine Exposure Benzodiazepines administered for sedation  Exposure Yes/No Dichotomous 
 
 
APPENDIX C 
Opioids and Delirium: Table of Evidence 
A literature search was conducted with National Library of Medicine Medical Subject 
Headings (MeSH) terms opioid AND delirium AND intensive care. Studies published 
between 1995 and 2019 were reviewed by using the PubMed database. Inclusion 
criteria included: 1) articles written in English; 2) search terms found in the title or as 
keywords; 3) study sample defined as adult population; 4) delirium as a primary or 
secondary outcome; and 5) intensive care unit setting. Exclusion criteria included: 1) 
articles related to the pediatric critical care setting; 2) mixed adult/pediatric studies; 3) 
case studies, commentaries, expert consensus, editorials and grey literature; 4) cancer 
pain populations and; 5) studies pertaining to general anesthesia management. The 
search strategy yielded 78 articles. After title and abstract review, 15 articles met 
inclusion criteria and were retained and evaluated for scientific rigor of study design, 
methods and analysis. Our literature search, article selection, and evaluation were 
guided by PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) for quality of reporting for systematic and meta-analyses. Using the Johns 
Hopkins Nursing Evidence-Based Practice Research Appraisal Guidelines, the design 
and quality of evidence of the articles were assigned an evidence level of I, II, III, IV or V 
and graded A (high quality) B (good quality) or C (low quality or major flaws) (see Table 
2.1). The Table has been  organized as to whether or not the findings supported an 
association between opioids and delirium, and the articles are summarized below. 
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First 
Author, 
Year, 
Country 
Study Aim Methodology, Study Design Sample Characteristics Major Findings/Outcomes Evidence 
Level & 
Grade 
Opioids Reduce Risk of Delirium 
Liu, 2017,  
China 
To investigate the influence 
of opioids and midazolam 
sedation on delirium and 
outcomes in critically ill 
patients and to analyze the 
risk factors of delirium. 
Single center, prospective randomized 
controlled trial 
Patients were randomly divided into three 
groups: 1) remifentanil and midazolam, 2)  
fentanyl and midazolam, and 3) the control 
group received only midazolam. 
Delirium assessed using the CAM-ICU. 
Patients admitted to the surgical 
intensive care unit who required 
sedation and were undergoing 
mechanical ventilation for longer 
than 24 hours. 
Sample Size: 105 
Age, mean (SD) 
Remifentanil and midazolam (n = 35) 
66 yrs (11.94 yrs) 
Fentanyl and midazolam (n = 35) 
62 yrs (9.96 yrs) 
Control Group - Midazolam (n = 35) 
64.49 yrs (10.01 yrs) 
40% of patients developed 
delirium. Significant 
differences were noted in 
delirium rates among the 
three groups (P = 0.014), 
22.9% for the remifentanil 
group, 40% for the fentanyl 
group, and 57.1% for the 
control group.  
Compared to the control 
group, remifentanil had a 
significantly lower rate of 
delirium (P = 0.007). 
The logistic regression 
analysis 
demonstrated that 
remifentanil (OR 0.230, 
95%Cl 0.074±0.711, P = 
0.011) is independent 
protective factor for delirium. 
Level I 
Grade B 
Agarwal, 
2010, 
United 
States 
To evaluate the prevalence 
of delirium in ventilated burn 
patients and to identify 
delirium risk factors. 
Retrospective, observational cohort study 
Burn patients often experience longer 
periods of mechanical ventilation and ICU 
care, making this a population at risk for 
developing delirium and its associated 
complications. 
Delirium assessed using the CAM-ICU. 
Adult burn patients receiving 
mechanical ventilation. 
Sample size: 82  
Age median (IQR): 48 yrs (38-62 yrs) 
The prevalence of delirium 
was 77% (63 of 82 patients) 
with a median duration of 3 
(1-6) days. 
Exposure to intravenous 
opiates (0.5 [0.4-0.6], P < 
.001) and methadone (0.7 
[0.5-0.9], P = .02) were 
associated with a lower risk 
of delirium. 
Opiates and methadone 
reduced the risk of 
developing delirium, possibly 
through reduction of pain in 
these patients. 
Level III 
Grade A 
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Opioids Not Associated with Delirium 
Sieber, 
2011, 
United 
States 
To determine the 
relationship between opioid 
consumption and cognitive 
impairment following hip 
fracture repair. 
Prospective study of consecutive patients. 
Pain, opioid consumption, and 
postoperative delirium was recorded. 
Delirium assessed using the CAM. 
Patients ≥65 years old undergoing 
hip fracture repair 
Sample Size: 236 
Age mean (SD): 81 yrs (7.1 yrs) 
Delirium (n = 60) 
83 yrs (6.9 yrs) 
Non delirium (n=176) 
81 yrs (7.1 yrs) 
There was no association 
between the use of any 
postoperative opioid and 
incident delirium (P = 0.615) 
Opioid dose (P ≥ 0.591) on 
postoperative days 1 and 2 
was not predictive of incident 
delirium. 
Level III 
Grade A 
Tedders, 
2014, 
United 
States 
To compare the efficacy and 
safety of fentanyl versus 
traditional sedation with 
propofol in critically ill 
patients receiving 
mechanical ventilation. 
Retrospective, observational cohort study 
Patients greater than 18 years of age 
receiving mechanical ventilation for a 
minimum of 24 hours were eligible for 
inclusion in this study. 
Delirium assessed using the CAM-ICU. 
Patients admitted to the ICU 
Sample Size: 100 
Age years, median (IQR) 
Fentanyl (n=50) 
70yr (59yr–83yr) 
Propofol (n=50) 
63yr (57yr–78yr) 
No difference in the rate of 
intensive care unit delirium 
was noted between groups 
(fentanyl 23% vs propofol 
27%, p=0.80). 
Level III 
Grade B 
Panharipan
de, 2006, 
United 
States 
To determine whether 
sedative and opioid 
analgesic medications 
independently increased the 
probability of daily transition 
to delirium. 
Cohort study 
Markov regression modeling (adjusting for 
11 covariates) was used to determine the 
probability of daily transition to delirium as 
a function of sedative (midazolam, 
propofol) and analgesic (fentanyl, 
morphine) dose administration during the 
previous 24 h. 
Delirium assessed using the CAM-ICU. 
Mechanically ventilated patient 
admitted to the medical or coronary 
ICUs 
Sample Size: 198 
Age, mean (SD): 56 yrs (17.0 yrs) 
Lorazepam was an 
independent risk factor for 
daily transition to delirium 
(OR, 1.2; P 0.003), although 
the  four medications were 
associated with trends toward 
significance (midazolam OR, 
1.7; P = 0.09; fentanyl OR, 
1.2; P = 0.09; morphine OR, 
1.1; P = 0.24; propofol OR, 
1.2; P = 0.18). 
Level III 
Grade A 
Shehabi, 
2009, 
Australia 
and New 
Zealand 
To assess the 
characteristics of 
dexmedetomidine compared 
with morphine-based 
regimen after cardiac 
surgery at equivalent levels 
of sedation and analgesia. 
Randomized, double-blind, controlled trial 
Study drug infusions were started in the 
ICU. The infusion was continued until the 
removal of chest drains, when patient was 
ready to discharge from ICU, or for up to 48 
hours of mechanical ventilation. 
Delirium assessed using the CAM-ICU. 
Cardiac surgery patients > 60 years 
Sample size: 306 
Age, Median (IQR) 
Dexmedetomidine (n=152) 
71.5 yrs (66 – 76 yrs)  
Morphine (n= 147) 
71 yrs (65 – 75 yrs) 
The incidence of delirium 
within 5 days was 11.7% (35 
of 299) with 8.6% occurring in 
the dexmedetomidine group 
and 15% occurring in the 
morphine group (RR 0.571, 
95% CI 0.256-1.099, p = 
0.088).  
Level I 
Grade A 
127 
Opioids Increase Risk of Delirium 
Dubois, 
2001, 
Canada 
To establish risk factors for 
the development of delirium 
in the ICU. 
Prospective study. 
Delirium was assessed by the intensivist 
and confirmed by formal psychiatric 
assessment.  
Consecutive patients aged 18 or 
older admitted to the ICU for > 24 
hours. 
Sample Size: 198 
Age, mean (SD) 
Delirium (n=38) 
63 yrs (13.9 yrs) 
No Delirium (n = 160) 
66 yrs (13.4 yrs) 
19% of patients developed 
delirium.  
In a multivariate analysis, 
morphine, in all dosages, was 
significantly linked to the 
development of delirium (OR 
between 6 and 9.2).  
Level III 
Grade A 
Marcantoni
o, 1994, 
United 
States 
To examine the role of 
medications with known 
psychoactive properties in 
the development of 
postoperative delirium. 
Nested case-control study within a 
prospective cohort study. 
Exposures to opioids, benzodiazepines, 
and anticholinergics were recorded for the 
24-hour period before delirium developed
in the 91 cases and for the same 24-hour
postoperative period for the 154 matched
controls.
Delirium assessed using the CAM. 
One or two controls were matched to 
each case of delirium. 
Sample Size: 245 
Age, mean (SD) 
Delirium (n=91) 
73 yrs (8 yrs) 
Controls (n=154) 
73 yrs (8 yrs) 
Delirium was significantly 
associated with postoperative 
exposure to meperidine 
(odds ratio [OR], 2.7; 95% 
confidence interval [CI], 1.3 
to 5.5). 
Opioids as a class of 
medication (OR, 1.4; 95% CI, 
0.5 to 4.3) were not 
significantly associated with 
delirium.  
Level III 
Grade A 
Clegg, 
2011, 
United 
Kingdom 
To identify prospective 
studies that investigated the 
association between 
medications and risk of 
delirium 
Meta-analysis 
Systematic review of randomized controlled 
trials, prospective cohort studies and case–
control studies that reported on 
medications and delirium in hospital 
patients or long-term care residents. 
Fourteen studies were included. 
Seven studies included opioid use 
across multiple settings (ICU and 
Hospital).  
Pooling data from two 
studies, delirium risk is 
increased with opioid 
administration (odds ratio 
[OR] 2.5, 95% CI 1.2-5.2). 
Level I 
Grade B 
Pisani, 
2009, 
United 
States 
The objective of this study 
was to examine the impact 
of benzodiazepine or opioid 
use on the duration of ICU 
delirium in an older medical 
population. 
Prospective cohort study. 
Recorded use of opioids (fentanyl and 
morphine), benzodiazepines (lorazepam 
and midazolam), and propofol on a daily 
basis. 
Delirium assessed using the CAM. 
Consecutive patients age 60 and 
older admitted to the medical ICU. 
Sample Size: 304 
Age, mean (SD): 75 yrs (8 yrs) 
Delirium (n=239) 
Benzodiazepine or Opioid Use 
(n=247) 
Delirium occurred in 79% of 
patients.  
The median duration of ICU 
delirium was 3 days with a 
range of 1-33 days.  
Receipt of an opioid (rate 
ratio [RR] 1.64, 95% 
confidence interval [CI] 1.27-
2.10) was associated with 
increased delirium duration. 
Level III 
Grade A 
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Burry, 
2017, 
Canada 
Investigate the relationship 
between benzodiazepines,  
propofol, opioids and 
delirium 
Prospective observational study 
During ICU admission, no patient was 
managed with a standardized sedation 
protocol (i.e., propofol, benzodiazepine). 
Delirium assessed using the Intensive Care 
Delirium Screening Checklist 
Critically ill adult patients admitted ≥ 
24h to 6 different intensive care units 
Sample Size: 520 
Age, mean (SD) 
No Delirium (n = 260) 
58 yrs (17.8 yrs) 
Delirium (n = 260) 
62 yrs (16.2 yrs) 
Delirium was detected in 260 
(50%) patients. The median 
(IQR) duration of delirium 
was 2 (1-5) days. 
Patients with delirium 
received more opioid 
(P=0.0008) drugs than 
patients without delirium. 
Level III 
Grade A 
Pisani, 
2010, 
United 
States 
To identify factors 
associated with persistent 
delirium in an older medical 
intensive care unit (ICU) 
population. 
Prospective cohort study 
Persistent delirium was defined as delirium 
occurring in the ICU and continuing upon 
discharge to the ward. 
Delirium assessed using the CAM. 
Consecutive admissions to the 
medical ICU patients 60 years or 
older 
Sample Size: 173 
Persistent delirium 58% (n = 100) 
Age > 75 (n=49) 
Non-persistent delirium 42% (n = 73) 
Age > 75 (n=24) 
In a multivariable logistic 
regression model, factors 
significantly associated with 
persistent delirium included 
age more than 75 years 
(odds ratio [OR], 2.52; 95% 
confidence interval [CI], 1.23-
5.16), and opioid (morphine 
equivalent) dose greater than 
54 mg/d (OR, 2.90; 95% CI, 
1.15-7.28). 
Level III 
Grade A 
Sosa, 
2017, 
Argentina 
To describe the incidence 
of and risk factors for 
delirium in the intensive care 
unit . 
Prospective observational study 
The PRE-DELIRIC model assesses 10 risk 
factors for delirium that are readily 
observable within the first 24 hours 
following ICU admission. 
Delirium assessed using the CAM. 
Patients admitted to the ICU 
Sample Size: 178 
Age mean (SD) 64.3 yrs (17.9 yrs) 
No Delirium (n=129) 
60.9 yrs (18.4 yrs) 
Delirium (n=49) 
74.4 yrs (9.4 yrs) 
27.5% of patients developed 
delirium.  
Predictive factors for the 
development of delirium were 
increased age, prolonged 
ICU stay, and opioid use (OR 
4.32; P = .003; CI: 1.64 – 
11.38). 
Level III 
Grade A 
APPENDIX D 
Propofol and Delirium: Table of Evidence 
A literature search was conducted with National Library of Medicine Medical Subject 
Headings (MeSH) terms propofol AND delirium. Studies published between 1995 and 
2019 were reviewed by using the PubMed database. Inclusion criteria included: 1) 
articles written in English; 2) search terms found in the title or as keywords; 3) study 
sample defined as adult population; 4) delirium as a primary or secondary outcome; and 
5) intensive care unit setting. Exclusion criteria included: 1) articles related to the
pediatric critical care setting; 2) mixed adult/pediatric studies; 3) case studies, 
commentaries, expert consensus, editorials and grey literature; 4) chronic or cancer pain 
populations and; 5) studies pertaining to general anesthesia management, not intensive 
care unit sedation. The search strategy yielded 51 articles. After abstract review, 15 
articles met inclusion criteria and were retained and evaluated for scientific rigor of study 
design, methods and analysis. Our literature search, article selection, and evaluation 
were guided by PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) for quality of reporting for systematic and meta-analyses. Using the Johns 
Hopkins Nursing Evidence-Based Practice Research Appraisal Guidelines (see Table 
2.1), the design and quality of evidence of the articles were assigned an evidence level 
of I, II, III, IV or V and graded A (high quality) B (good quality) or C (low quality or major 
flaws). The Table has been organized according to comparators: propofol and delirium, 
opioids,  benzodiazepines and dexmedetomidine. The articles are summarized below. 
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First Author, 
Year, Country 
Study Aim Methodology, Study Design Sample Characteristics Major Findings/Outcomes Evidence 
Level & 
Grade 
Propofol and Delirium 
Jiang, 2017, 
China 
To analyze various risk 
factors for 
postoperative delirium 
after spine surgery in 
the middle- and old-
aged patients. 
Retrospective cohort study 
 
Delirium assessed using cognitive 
tests consisting of Clinical Dementia 
Rating and Global Deterioration Scale. 
Patients who underwent spinal surgery. 
 
Sample Size: 451 patients  
Age, mean (SD), years: 65 (18.3) years 
A total of 42 (9.3 %) patients 
were diagnosed with delirium. 
 
Delirious and non-delirious 
patients had no difference in 
use of propofol. 
Level III 
Grade B 
Mori, 2016, 
Brazil 
To identify the 
incidence of delirium, 
compare the 
demographic and 
clinical characteristics 
of patients with and 
without delirium. 
Prospective cohort study 
 
Delirium assessed using the CAM-
ICU. 
Patients admitted to the Intensive Care 
Unit 
 
Sample Size: 149  
Age years, median (IQR)  
 
With Delirium (n=69) 
65 (22.0 yr)  
 
Without Delirium (n=80) 
54 (24.3 yr)  
Of the total 149 patients in the 
sample, 69 (46.3%) developed 
delirium during ICU stay. 
 
Propofol was utilized in 33% of 
patients with delirium compared 
to just 7.5% of patients without 
delirium (p < 0.001). 
Level III 
Grade A 
Bryczkowski, 
2014, United 
States 
This study aimed to 
identify modifiable 
factors that would 
predict delirium in an 
older trauma 
population admitted to 
the SICU. 
Prospective cohort study 
 
Delirium assessed using the CAM-
ICU. 
Consecutive patients older than 50 
years, admitted to the SICU. 
 
Sample Size: 115  
Age, mean (95% CI) 
 
With Delirium (n=69) 
68yr (65yr – 71yr)  
 
Without Delirium (n=46) 
65yr (62yr – 68yr)  
 
 
 
 
 
 
 
 
 
 
 
The average propofol dose in 
patients with delirium was 6 
mg/kg/d compared to 1 mg/kg/d 
in patients without delirium 
(p<0.001). 
 
Significant risk factors 
influenced by clinical treatment 
included doses propofol. 
Level III 
Grade C 
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Comparison Studies – Opioids 
Tedders, 2014, 
United States 
To compare the 
efficacy and safety of 
fentanyl versus 
traditional sedation 
with propofol in 
critically ill patients 
receiving mechanical 
ventilation. 
Retrospective, observational cohort 
study 
 
Patients greater than 18 years of age 
receiving mechanical ventilation for a 
minimum of 24 hours were eligible for 
inclusion in this study. 
 
Delirium assessed using the CAM-
ICU. 
Patients admitted to the ICU 
 
Sample Size: 100 
Age years, median (IQR) 
 
Fentanyl (n=50)  
70yr (59yr–83yr) 
 
Propofol (n=50) 
63yr (57yr–78yr) 
 
No difference in the rate of 
intensive care unit delirium was 
noted between groups (fentanyl 
23% vs propofol 27%, p=0.80). 
Level III 
Grade B 
Comparison Studies – Benzodiazepines 
Seymour, 
2012, United 
States 
To determine whether 
benzodiazepine and 
propofol doses are 
increased at night and 
whether daytime and 
nighttime sedative 
doses are associated 
with delirium, coma, 
and delayed liberation 
from mechanical 
ventilation. 
Single-center, prospective cohort 
study 
 
Hourly doses of benzodiazepine and 
propofol exposure were measured 
during the daytime (7 AM to 11 PM) 
and nighttime (11 PM to 7 AM) for 5 
days. 
 
Delirium assessed using the CAM-
ICU. 
 
Adult patients receiving mechanical 
ventilation for >12 hrs. 
 
Sample Size: 140  
Age, median (IQR): 66yr (55yr–75yr) 
 
Higher daytime propofol doses 
were marginally associated with 
delirium (p = .06), whereas 
nighttime change in propofol 
dose was not associated with 
delirium the following day (p = 
.27). 
Level III 
Grade B 
Comparison Studies – Dexmedetomidine 
Maldonado, 
2009, United 
States 
Investigated the effects 
of postoperative 
sedation on the 
development of 
delirium in patients 
undergoing cardiac-
valve procedures. 
Randomized, open-label, controlled 
trial 
 
After weaning from bypass, patients 
were randomly assigned to 
postoperative sedation regimens. 
Patients were extubated while still on 
the medication and were kept on the 
maintenance infusion as deemed 
clinically necessary for a maximum of 
24 hours. 
 
Delirium assessed by a trained 
neuropsychiatrist. 
Patients schedule for elective cardiac 
valve operations.  
 
Sample size: 118 randomized, 90 
analyzed. 
Age, mean (SD) 
 
Dexmedetomidine (n= 40) 
55yr (16yr)  
 
Propofol (n= 38) 
58yr (18yr)  
 
Midazolam (n= 40) 
60yr (16yr)  
Using a per-protocol analysis, 
the incidence of delirium for the 
entire study population was 
34% (31/90). 
 
The incidence of delirium was 
statistically different between 
the three groups (p < 0.001): 
Dexmedetomidine = 3% (1/30) 
Propofol =  50% (15/30)  
Midazolam = 50% (15/30)  
 
 
 
Level I 
Grade A 
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Subramaniam, 
2019, United 
States 
To evaluate the effect 
of postoperative 
intravenous (IV) 
acetaminophen vs 
placebo combined with 
IV propofol vs 
dexmedetomidine on 
postoperative delirium 
among older patients 
undergoing cardiac 
surgery. 
Randomized, placebo-controlled trial  
 
Patients were randomized to one of 
four groups; postoperative analgesia 
with acetaminophen or placebo (0.9% 
saline) and postoperative sedation 
with dexmedetomidine or propofol. 
 
Delirium assessed using the CAM-
ICU. 
Patients undergoing cardiac surgery. 
 
Sample size: 120 patients 
Age; median (IQR) 
 
Acetaminophen and dexmedetomidine 
(n = 29) 
64yr (63yr-72yr)  
 
Placebo and dexmedetomidine (n = 30) 
69yr (63yr-74yr)  
 
Acetaminophen and propofol (n = 31) 
70yr (66yr-75yr)  
 
Placebo and propofol (n = 30) 
71yr (64yr-79yr) 
Delirium was reported in 21% of 
patients receiving propofol vs 
17% of patients receiving 
dexmedetomidine.  
 
No significant difference in 
delirium between groups was 
reported ((difference, -4%) p = 
.54). 
Level I 
Grade A 
 
Chuich, 2019, 
United States 
This study evaluates 
the effects of the 
intraoperative and 
postoperative use of 
dexmedetomidine 
versus propofol 
infusions. 
Retrospective observational study 
 
Patients received either 
dexmedetomidine or propofol infusion 
in addition to general anesthesia 
intraoperatively and as a 
postoperative sedative. 
 
Delirium assessed using the CAM-
ICU. 
Patients undergoing cardiac surgery. 
 
Sample size: 278 patients  
Age; median (range) 
 
Dexmedetomidine (n = 69)  
63yr (56yr-71yr)  
 
Propofol (n = 209) 
67yr (58yr-74yr)  
There was no significant 
association between use of 
dexmedetomidine or propofol 
and incidence of delirium (p = 
0.27) after adjusting for 
covariates. 
Level III 
Grade A 
Liu, 2017, 
United States 
To compare the effects 
of dexmedetomidine 
and propofol sedation 
on outcomes in adult 
patients after cardiac 
surgery. 
Meta-analysis  
 
 
Patients undergoing cardiac surgery. 
 
Sample size: 969  
8 studies met the selection criteria  
 
4 studies (Liu 2016; Corbett 2005; 
Djaiani 2016; Maldonado 2009) used 
propofol as a comparator with a total 
number of 393 accrued participants. 
 
Pooling of data from 4 studies 
showed the incidence of 
delirium to be 23.5% in the 
propofol group compared to 
9.3% in the dexmedetomidine 
group (p < 0.001). 
 
Meta-analysis showed that the 
dexmedetomidine sedation 
significantly decreased 
postoperative delirium (POD; 
RR, 0.40; 95% CI, 0.24-0.64; P 
= .0002). 
Level I 
Grade A 
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Liu, 2016, 
United States 
To compare the effects 
of dexmedetomidine 
and propofol on 
sublingual 
microcirculation in 
patients after cardiac 
surgery. 
Prospective, randomized, single-blind 
study 
 
Patients were assigned randomly to 
receive either dexmedetomidine or 
propofol upon admission to the ICU. 
 
 
Delirium assessed using the CAM-
ICU. 
 
Patients undergoing cardiac surgery. 
 
Sample Size: 61 
Age, median (range) 
 
Propofol (n = 32)  
55yr (48yr-62yr) 
 
Dexmedetomidine (n = 29) 
53yr (48yr-63yr) 
Incidence of delirium was 6% in 
the propofol group, compared to 
0% in the dexmedetomidine 
group (p = 0.493). 
Level I 
Grade C 
 
Jiang, 2016, 
United States 
To assess the 
prevalence of delirium 
in mechanically 
ventilated patients 
sedated with 
dexmedetomidine or 
propofol. 
Retrospective cohort study 
 
Patients received either 
dexmedetomidine or propofol for 24 
hours or more for sedation. 
 
Delirium assessed using the CAM-
ICU. 
 
Patients admitted to the medical or 
surgical intensive care units. 
 
Sample Size: 111  
Age, years (range)  
 
Dexmedetomidine (n= 56)  
73yr (50yr–94yr) 
 
Propofol (n = 55)  
68yr (22yr–93yr) 
The rates of delirium were 
similar in both groups, with 20% 
in propofol-treated patients vs. 
16% in the dexmedetomidine 
group (p = 0.63).  
Level III 
Grade B 
Djaiani, 2016, 
Canada 
To assess if 
dexmedetomidine in 
comparison to propofol 
sedation after cardiac 
surgery would reduce 
the incidence of 
postoperative delirium. 
Single-blind, prospective, randomized 
controlled trial  
 
Upon arrival to ICU, sedation was 
initiated. The infusion was continued 
for a maximum period of 24 hours.  
 
 
Delirium assessed using the CAM-
ICU. 
Patients undergoing cardiac surgery. 
 
Sample size: 185 
Age, mean (SD) 
 
Dexmedetomidine (n= 91) 
73yr (6.4yr)  
 
Propofol (n= 92) 
73yr (6.2yr)  
A total of 17.5% and 31.1% of 
patients in the 
dexmedetomidine and propofol 
groups respectively, developed 
delirium (p = 0.028). 
 
Level I 
Grade A 
 
Wanat, 2014, 
United States 
This study compares 
sedation with 
dexmedetomidine 
versus propofol in 
mechanically ventilated 
patients after 
cardiovascular surgery. 
Retrospective cohort study 
 
Sedation orders were based on 
individual physician ordering upon 
arrival to the ICU.  
 
 
Delirium assessed using the CAM-
ICU. 
 
Patients admitted to the ICU after 
cardiovascular surgery. 
 
Sample size: 352 
Age, mean (SD) 
 
Dexmedetomidine (n= 33) 
63yr (14.1yr) 
 
Propofol (n= 319) 
68yr (11.2yr)  
CAM-ICU scores were reported 
in 79% of dexmedetomidine 
patients and 84% of propofol 
patients (p = 0.411).  
 
Incidence of delirium (any vs. 
none) was similar between both 
groups (9.09% vs. 7.52%, p = 
0.747). 
Level III 
Grade B 
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Xia, 2013, 
China 
To assess the 
influence of 
dexmedetomidine 
and propofol sedation 
on adverse events for 
adults in the intensive 
care unit. 
Meta-analysis  
 
The primary outcomes of this study 
were length of ICU stay, duration of 
mechanical ventilation, and risk of ICU 
mortality. Secondary outcomes 
included risk of delirium. 
Ten randomized controlled trials, 
involving 1202 patients, were included. 
 
Three studies (Maldonado 2009; 
Corbett 2005; Jakob 2012) comprised 
of 658 patients, reported the incidence 
of delirium.  
 
Delirium rates were significantly 
lower with dexmedetomidine 
compared with those with 
propofol (RR, 0.40; 95% CI, 
0.22-0.74; p = 0.003). 
 
Level I 
Grade A 
 
Corbett, 2005, 
United States 
To assessed patient-
perceived satisfaction 
with coronary artery 
bypass graft surgery 
after administration of 
dexmedetomidine or 
propofol for sedation. 
Prospective, randomized clinical study 
 
Patients were randomized to either 
dexmedetomidine or propofol. 
 
Delirium was assessed by a modified 
Hewitt-sedation questionnaire was 
administered by the study investigator. 
Patients in the surgical ICU following 
cardiac surgery. 
 
Sample size: 89 
Age mean (SD) 
 
Dexmedetomidine (n = 43) 
64yr (10.1yr) 
 
Propofol (n = 46) 
63yr (10.7yr) 
One episode of delirium 
occurred in the 
dexmedetomidine treatment 
arm and one episode occurred 
in the propofol treated patients. 
Level I 
Grade C 
 
 
 
 
  
 
